

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199887460 B2
(10) Patent No. 755794

(54) Title
Interleukin-18 binding proteins, their preparation and use

(51)⁶ International Patent Classification(s)
C07K 014/54

(21) Application No: **199887460**

(22) Application Date: **1998 .08 .13**

(87) WIPO No: **WO99/09063**

(30) Priority Data

(31) Number	(32) Date	(33) Country
121554	1997 .08 .14	IL
121639	1997 .08 .27	IL
121860	1997 .09 .29	IL
122134	1997 .11 .06	IL
125463	1998 .07 .22	IL

(43) Publication Date : **1999 .03 .08**

(43) Publication Journal Date : **1999 .05 .06**

(44) Accepted Journal Date : **2002 .12 .19**

(71) Applicant(s)
Yeda Research and Development Co. Ltd.

(72) Inventor(s)
Daniela Novick; Charles Dinarello; Menachem Rubinstein; Soo Hyun Kim

(74) Agent/Attorney
F.B. RICE and CO., 139 Rathdowne Street, CARLTON VIC 3053

OPI DATE 08/03/99 APPLN. ID 87460/98
AOJP DATE 06/05/99 PCT NUMBER PCT/IL98/00379



AU9887460

<p>(51) International Patent Classification ⁶ : C07K 14/54</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/09063 (43) International Publication Date: 25 February 1999 (25.02.99)</p>
<p>(21) International Application Number: PCT/IL98/00379 (22) International Filing Date: 13 August 1998 (13.08.98) (30) Priority Data: 121554 14 August 1997 (14.08.97) IL 121639 27 August 1997 (27.08.97) IL 121860 29 September 1997 (29.09.97) IL 122134 6 November 1997 (06.11.97) IL 125463 22 July 1998 (22.07.98) IL (71) Applicant (for all designated States except US): YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): NOVICK, Daniela [IL/IL]; Hanassi Harishon 40, 76302 Rehovot (IL). DINARELLO, Charles [US/US]; 333 15th Street, Boulder, CO 80302 (US). RUBINSTEIN, Menachem [IL/IL]; 16 Hatomer Street, 54042 Givat Shmuel (IL). KIM, Soo, Hyun [KR/IL]; Hamaapil Street 4, 76348 Rehovot (IL). (74) Agent: EINAV, Henry; Inter-Lab Ltd., Science-based Industrial Park, Kiryat Weizmann, 76110 Ness-Ziona (IL).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: INTERLEUKIN-18 BINDING PROTEINS, THEIR PREPARATION AND USE</p> <p>(57) Abstract</p> <p>Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.</p>		

INTERLEUKIN-18 BINDING PROTEINS,**THEIR PREPARATION AND USE****Field of the Invention**

5 The present invention relates to interleukin-18 (IL-18) binding protein, hereinafter IL-18BP, capable of binding IL-18. More particularly, this invention relates to a soluble IL-18BP obtainable from body fluids, to soluble IL-18BPs obtainable by expression of suitable DNA vectors in host cells, to virus-encoded homologues of IL-18BP obtainable by expression of suitable DNA vectors in host cells, to vectors expressing the various IL-18BPs,
10 to vectors useful for expression of IL-18BP in humans and other mammals, to antibodies against IL-18BPs, to therapeutic use of said IL-18BPs by modulating and/or blocking IL-18 activity, to therapeutic use of said expression vectors in modulating and/or blocking IL-18 activity and to use of the antibodies.

Background of the Invention

15 In 1989, an endotoxin-induced serum activity that induced interferon- γ (IFN- γ) obtained from mouse spleen cells was described (27). This serum activity functioned not as a direct inducer of IFN- γ but rather as a co-stimulant together with IL-2 or mitogens. An attempt to purify the activity from post-endotoxin mouse serum revealed an apparently homogeneous 50-55 kDa protein (26). Since other cytokines can act as co-stimulants for
20 IFN- γ production, the failure of neutralizing antibodies to IL-1, IL-4, IL-5, IL-6, or TNF to neutralize the serum activity suggested it was a distinct factor. In 1995, the same scientists demonstrated that the endotoxin-induced co-stimulant for IFN- γ production was present in extracts of livers from mice preconditioned with *P. acnes* (31). In this model, the hepatic macrophage population (Kupffer cells) expand and in these mice, a low dose of bacterial
25 lipopolysaccharide (LPS), which in non-preconditioned mice is not lethal, becomes lethal. The factor, named IFN- γ -inducing factor (IGIF) and later designated interleukin-18 (IL-18), was purified to homogeneity from 1,200 grams of *P. acnes*-treated mouse livers. Degenerate oligonucleotides derived from amino acid sequences of purified IL-18 were used to clone a

murine IL-18 cDNA (31). IL-18 is an 18-19 kDa protein of 157 amino acids, which has no obvious similarities to any peptide in the databases. Messenger RNAs for IL-18 and interleukin-12 (IL-12) are readily detected in Kupffer cells and activated macrophages. Recombinant IL-18 induces IFN-gamma more potently than does IL-12, apparently through a
5 separate pathway (31). Similar to the endotoxin-induced serum activity, IL-18 does not induce IFN- γ by itself, but functions primarily as a co-stimulant with mitogens or IL-2. IL-18 enhances T cell proliferation, apparently through an IL-2-dependent pathway, and enhances Th1 cytokine production *in vitro* and exhibits synergism when combined with IL-12 in terms of enhanced IFN- γ production (24).

10 Neutralizing antibodies to mouse IL-18 were shown to prevent the lethality of low-dose LPS in *P. acnes* pre-conditioned mice. Others had reported the importance of IFN- γ as a mediator of LPS lethality in pre-conditioned mice. For example, neutralizing anti-IFN- γ antibodies protected mice against Shwartzman-like shock (16), and galactosamine-treated mice deficient in the IFN- γ receptor were resistant to LPS-induced death (7). Hence, it was
15 not unexpected that neutralizing antibodies to murine IL-18 protected *P. acnes*-preconditioned mice against lethal LPS (31). Anti-murine IL-18 treatment also protected surviving mice against severe hepatic cytotoxicity.

After the murine form was cloned, the human cDNA sequence for IL-18 was reported in 1996 (38). Recombinant human IL-18 exhibits natural IL-18 activity (38). Human
20 recombinant IL-18 is without direct IFN- γ -inducing activity on human T-cells, but acts as a co-stimulant for production of IFN- γ and other T-helper cell-1 (Th1) cytokines (38). To date, IL-18 is thought of primarily as a co-stimulant for Th1 cytokine production (IFN- γ , IL-2 and granulocyte-macrophage colony stimulating factor) (20) and also as a co-stimulant for FAS ligand-mediated cytotoxicity of murine natural killer cell clones (37).

25 By cloning IL-18 from affected tissues and studying IL-18 gene expression, a close association of this cytokine with an autoimmune disease was found. The non-obese diabetic (NOD) mouse spontaneously develops autoimmune insulinitis and diabetes, which can be accelerated and synchronized by a single injection of cyclophosphamide. IL-18 mRNA was demonstrated by reverse transcriptase PCR in NOD mouse pancreas during early stages of
30 insulinitis. Levels of IL-18 mRNA increased rapidly after cyclophosphamide treatment and

preceded a rise in IFN- γ mRNA, and subsequently diabetes. Interestingly, these kinetics mimic that of IL-12-p40 mRNA, resulting in a close correlation of individual mRNA levels. Cloning of the IL-18 cDNA from pancreas RNA followed by sequencing revealed identity with the IL-18 sequence cloned from Kupffer cells and in vivo pre-activated macrophages.

5 Also NOD mouse macrophages responded to cyclophosphamide with IL-18 gene expression while macrophages from Balb/c mice treated in parallel did not. Therefore, IL-18 expression is abnormally regulated in autoimmune NOD mice and closely associated with diabetes development (32).

10 IL-18 plays a potential role in immunoregulation or in inflammation by augmenting the functional activity of Fas ligand on Th1 cells (10). IL-18 is also expressed in the adrenal cortex and therefore might be a secreted neuro-immunomodulator, playing an important role in orchestrating the immune system following a stressful experience (9).

In vivo, IL-18 is formed by cleavage of pro-IL-18, and its endogenous activity appears to account for IFN- γ production in *P. acnes* and LPS-mediated lethality. Because of
15 its activity, blocking the biological activity of IL-18 in human disease is a therapeutic strategy in many diseases. This can be accomplished using soluble receptors or blocking antibodies to the cell-bound IL-18 receptor.

Cytokine binding proteins (soluble cytokine receptors) correspond to the extracellular ligand binding domains of their respective cell surface cytokine receptors. They are derived
20 either by alternative splicing of a pre-mRNA, common to the cell surface receptor, or by proteolytic cleavage of the cell surface receptor. Such soluble receptors have been described in the past, including among others, the soluble receptors of IL-6 and IFN- γ (30), TNF (11, 12), IL-1 and IL-4 (21), IFN- α/β (28, 29) and others. One cytokine-binding protein, named osteoprotegerin (OPG, also known as osteoclast inhibitory factor - OCIF), a member of the
25 TNFR/Fas family, appears to be the first example of a soluble receptor that exists only as a secreted protein (1, 34, 39).



Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were
5 common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not
10 the exclusion of any other element, integer or step, or group of elements, integers or steps.

SUMMARY OF THE INVENTION

The present invention provides IL-18 binding proteins (IL-18 BPs) and virally encoded IL-18 BP homologues (hereinafter, viral IL-18 BPs), and fused
15 proteins, muteins, functional derivatives, active fragments and circularly permuted derivatives thereof,



capable of binding to IL-18. The invention also provides a process for isolating IL-18 BPs from human fluids, and a process to obtain them by recombinant means. The invention also provides expression vectors of IL-18 BPs, suitable for expression of IL-18 BP in humans and other mammals. Specific IL-18 BPs, virally encoded IL-18 BP homologues, fused proteins, muteins, functional derivatives, active fragments and circularly permuted derivatives thereof of the present invention are useful for modulating and/or blocking the biological activities of IL-18. Particular polypeptides of the invention are as follows:

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence selected from the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA112 of SEQ ID NO:4 AA29-AA112 of SEQ ID NO:4 AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6, AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID NO:8,
- (b) a mutein of any one of the sequences in (a), wherein the amino acid sequence of said mutein has at least 40% identity to at least one of the sequences in (a).

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence selected from the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA197 of SEQ ID NO:6, and AA29-AA197 of SEQ ID NO:6,
- (b) a mutein of any one of the sequences in (a), wherein the amino acid sequence of the said mutein has at least 40% identity to at least one of the sequences in (a);

wherein the polypeptide of (a) or (b) binds to IL-18.

Isolated polypeptides comprising:

- (i) the amino acid sequence of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, or conservative amino acid substituents thereof;
- (ii) an isolated polypeptide comprising the amino acid sequence of AA1-AA112 of SEQ ID NO:4 AA29-AA112 of SEQ ID NO:4 or conservative amino acid substituents thereof;
- (iii) an isolated polypeptide comprising the amino acid sequence of AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6, or conservative amino acid substituents thereof;



- (iv) an isolated polypeptide comprising the amino acid sequence of AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID NO:8, or conservative amino acid substituents thereof; or
- (v) an isolated polypeptide that includes the amino acid sequence of AA29-40 of SEQ ID NO:2 or AA1-AA40 of SEQ ID NO: 10, wherein the polypeptide binds to IL-18 and modulates or blocks the biological activity of IL-18.

A purified IL-18 binding protein (IL-18 BP), wherein the protein is characterized as follows:

- (a) the protein has a molecular weight of about 40 kD as measured by SDS-PAGE in its originally glycosylated form;
- (b) the protein binds to IL-18, and modulates or blocks the activity of IL-18; and
- (c) the protein has an N-terminal sequence that includes the amino acid sequence of AA29-40 of SEQ ID NO:2 or AA1-AA40 of SEQ ID NO:10, or conservative amino acid substituents thereof.

An isolated IL-18 BP polypeptide having an N-terminal sequence that includes the amino acid sequence of AA29-40 of SEQ ID NO:2 or AA1-AA40 of SEQ ID NO: 10, or conservative amino acid substituents thereof, and an Ig domain, wherein the polypeptide binds to IL-18, and modulates or blocks the activity of IL-18.

Also provided are active fragments of the IL-18 BP proteins or polypeptides of the invention, wherein the active fragment binds to IL-18, and modulates or blocks the activity of IL-18.

The particular nucleic acid molecules provided by the invention include the following:

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of

- (a) an amino acid sequence selected from the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA112 of SEQ ID NO:4 AA29-AA112 of SEQ ID NO:4 AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6, AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID NO:8,
- (b) a mutein of any one of the sequences in (a), wherein the amino acid sequence of said mutein has at least 40% identity to at least one of



the sequences in (a).

An isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of:

- 5 (a) a nucleic acid sequence of SEQ ID NO: 1 encoding AA1-AA192 of SEQ ID NO:2 or AA29-AA192 of SEQ ID NO:2
- (b) a nucleic acid sequence of SEQ ID NO: 3 encoding AA1-AA112 of SEQ ID NO:4 or AA29-AA112 of SEQ ID NO:4;
- (c) a nucleic acid sequence of SEQ ID NO: 5, encoding AA1-AA197 of
10 SEQ ID NO:6 or AA29-AA197 of SEQ ID NO:6;
- (d) a nucleic acid sequence of SEQ ID NO: 7, encoding AA1-AA161 of SEQ ID NO:8, or AA29-AA161 of SEQ ID NO:8;
- (e) a nucleic acid sequence whose complement binds, under high stringency conditions, to any one of the nucleic acid sequences in (a) through (d) and which encodes an amino acid sequence selected from
15 the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA112 of SEQ ID NO:4 AA29-AA112 of SEQ ID NO:4 AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6, AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID NO:8.

20 An isolated nucleic acid molecule containing the nucleic acid sequence of SEQ ID NO: 9, or a nucleic acid sequence whose complement binds, under high stringency conditions, thereto.

An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, and 7 or a mature
25 protein encoding portion of any one of SEQ ID NO: 1, 3, 5, and 7.

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

- 30 (a) an amino acid sequence selected from the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6,
- (b) a mutein of any one of the sequences in (a), wherein the amino acid sequence of said mutein has at least 40% identity to at least one of the sequences in (a);

35 wherein said nucleic acid molecule encodes for a polypeptide that binds IL-



An isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of:

- (a) a nucleic acid sequence of SEQ ID NO: 1 encoding AA1-AA192 of SEQ ID NO:2 or AA29-AA192 of SEQ ID NO:2
- 5 (b) a nucleic acid sequence of SEQ ID NO: 5, encoding AA1-AA197 of SEQ ID NO:6 or AA29-AA197 of SEQ ID NO:6;

A recombinant DNA molecule comprising a nucleic acid molecule of the invention ligated to a second nucleic acid encoding a second polypeptide wherein on expression, said DNA construct encodes a fusion protein

10 comprising IL-18 BP or a fragment thereof, fused to the second polypeptide.

The invention also provides a DNA primer having a nucleotide sequence selected from the group consisting

(a) TATATCTAGAGCCACCATGAGACACAACCTGGAACCA, and

(b) ATATCTAGATTAATGATGATGATGATGATGACCCTGCTGCTGTGGACTGC

15 The nucleic acid molecules and polypeptides described herein find use in the following methods of the invention:

A method for identifying, isolating or amplifying an IL-18 BP encoding nucleic acid sequence, comprising using the isolated nucleic acids of the invention as a primer or probe.

20 A method for production of the polypeptide described herein, comprising culturing a host cell of the invention under conditions suitable for expression of said polypeptide.

A method for detecting an IL-18 BP in a sample, comprising contacting said sample with an antibody against IL-18 and further detecting the presence

25 of bound antibody.

A method for purifying an IL-18 BP polypeptide, comprising contacting an IL-18 BP sample with an IL-18 BP antibody removing unbound protein in the sample and then eluting the bound IL-18 BP.

A process for the isolation or purification of an IL-18 BP, comprising:


30 (a) passing a sample through a chromatographic column to which IL-18 is coupled;

(b) washing the column to remove unbound protein in the sample, and

(c) eluting the bound IL-18 BP.

A process for the isolation or purification of an IL-18 BP, comprising

35 contacting a sample with a substrate to which IL-18 is coupled, removing unbound protein in the sample and then eluting the bound IL-18 BP.



A method for the preparation of an IL-18 BP derivative comprising preparing a DNA construct that encodes an IL-18 BP polypeptide ligated to a nucleic acid encoding a second polypeptide, wherein on expression, said DNA construct encodes a fusion protein comprising an IL-18 BP polypeptide fused to
 5 the second polypeptide.

A method for the preparation of an IL-18 BP derivative comprising chemically modifying a polypeptide of the invention to include at least one derivative moiety.

The present invention further provides methods of treating or
 10 preventing a disease associated with an excess of IL-18, said method comprising administering to a subject in which such treatment or prevention is desired, a pharmaceutical composition of the invention in an amount sufficient to treat or prevent said disease in said subject. The disease may be selected from the group consisting of autoimmune diseases, Type 1 diabetes,
 15 rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease, ischemic brain injury, chronic hepatitis, acute hepatitis, psoriasis, chronic pancreatitis.

Replicable expression vehicles containing DNAs suitable for expression of the various IL-18 BPs in host cells, host cells transformed herewith and
 20 proteins and polypeptides produced by expression of such hosts are also provided.

The invention further provides pharmaceutical compositions consisting of suitable vehicles and IL-18 BPs, or viral IL-18 BPs, or vectors for expressing same in humans and other mammals or antibodies to IL-18 BPs or nucleic acid
 25 molecules encoding IL-18 BP, for the treatment of diseases or conditions which require modulation or blocking of IL-18 activity. Also provided are kits comprising in one or more vials, the pharmaceutical compositions.

The invention further provides antibodies to the IL-18 BPs and the viral IL-18 BPs, suitable for affinity purification and immunoassays of same.

30 **Description of the Figures**

Figure 1 shows SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) of ligand affinity purified IL-18 binding protein. Crude urinary proteins (concentrated by ultrafiltration of 500 L normal human urine) were loaded on an IL-18-agarose column. The column was washed and bound
 35 proteins eluted at pH 2.2. Eluted fractions were neutralized and aliquots were analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and



silver staining. The lanes are: 1: crude urinary proteins (1.5 μ g, loaded on the gel); 209 elutions 1-8, respectively, from the IL-18-agarose column; 10: molecular weight markers, in kD, as indicated on the right side. An arrow indicates the band corresponding to IL-18 BP.

5 **Figure 2** shows an autoradiogram of SDS-PAGE (7.5% acrylamide) of complexes consisting of 125 I-IL-18 (apparent molecular weight 19 kD), cross-linked to the following

9
5

9
3
9



preparations of soluble IL-18 binding protein: Lane 1: Wash of the IL-18 affinity column. Lane 2: Elution 2 of the IL-18 affinity column. Lane 3: Elution 3 of the IL-18 affinity column. Molecular weight markers are indicated on the right side (in kD). An arrow indicates the cross-linked product (58 kD).

5

Figure 3 shows inhibition of IL-18-induced production of IFN- γ by IL-18BP

(A) Mouse splenocytes were stimulated (24 hr, 37°C) with the indicated combinations of LPS (1 μ g/ml) and human IL-18 (5 ng/ml), added either directly, or after pre-mixing (1 h, 37°C) with urinary IL-18BP. The level of murine IFN- γ in the culture was determined after 24 hr.

10 (B) Mouse splenocytes were incubated (24 h) with LPS (1 μ g/ml) together with murine IL-18 (10 ng/ml) pre-mixed (1 h, 37°C) with increasing concentrations of human IL-18BP.

(C) Mouse splenocytes were incubated (24 h) with LPS (10 μ g/ml) together with increasing concentrations of human IL-18BP.

15 (D) Mouse splenocytes were incubated (24 h) with Con A (1 μ g/ml), together with increasing concentrations of human IL-18BP.

(E) Human KG-1 cells were stimulated with TNF- α (20 ng/ml) and huIL-18 (25 ng/ml), added either alone, or after pre-mixing (1 h, 37°C) with urinary IL-18BP.

20 **Figure 4** shows the sequence of human IL-18BP_a cDNA and protein. The signal peptide is underlined.

Figure 5 shows the sequence of human IL-18BP_b cDNA and protein. The signal peptide is underlined.

25 **Figure 6** shows the sequence of human IL-18BP_c cDNA and protein. The signal peptide is underlined.

Figure 7 shows the sequence of human IL-18BP_d cDNA and protein. The signal peptide is underlined.

30

Figure 8 shows the sequence of human IL-18BP gene. The sequence of a human genomic clone (7.1 kb) was determined and compared with that of the various cDNA clones isolated from 3 cDNA libraries. the common translation start codon is nucleotides 683-685. The NuMA1 gene is located on the negative strand, from nucleotide 3578 to the end.

5

Figure 9 shows the effect of recombinant IL-18BP on human and mouse IL-18 activity.

His₆-tagged IL-18BP_a was transiently expressed in COS7 cells and purified.

(A) Human IL-18 (5 ng/ml) was pre-mixed with either His₆-tagged-IL-18BP_a or RPMI and added to mouse spleen cells together with LPS (1 µg/ml). IFN-γ production was measured after 24 h.

(B) Mouse IL-18 (10 ng/ml) was pre-mixed with either His₆-tagged-IL-18BP_a or RPMI and added to mouse spleen cells together with LPS (1 µg/ml). IFN-γ production was measured after 24 h.

(C) Human IL-18 (25 ng/ml) was pre-mixed with either COS7-IL-18BP_a or RPMI and added to Human PBMC in the presence of IL-12 (10 ng/ml).

(D) Human IL-18 (25 ng/ml) was pre-mixed with either COS7-IL-18BP_a or RPMI and added to Human KG-1 cells in the presence of TNF-α (20 ng/ml).

20 Detailed Description of the Invention

The present invention relates to various IL-18BPs and viral IL-18BPs which bind to IL-18. Such IL-18BPs may be capable of modulating and/or blocking the biological activities of IL-18. The term, "IL-18BPs and viral IL-18BPs," includes the mature protein (without the signal sequence), the protein comprising signal sequences, muteins of IL-18BPs and viral IL-18BPs, derivatives of IL-18BPs and viral IL-18BPs and truncated forms of IL-18BPs and viral IL-18BPs and salts thereof.

The invention further relates to replicable expression vehicles, suitable for expression of various IL-18BPs or viral IL-18BPs in host cells and host bacteria. The invention further relates to expression vectors, suitable for expression of various IL-18BPs or viral IL-18BPs in humans and in other mammals.

30

The invention further relates to DNAs coding for various IL-18BPs, viral IL-18BPs, muteins, fused proteins, functional derivatives, active fractions and mixtures thereof. Said DNA may be a genomic DNA, a cDNA, a synthetic DNA, a PCR product or combinations thereof. These DNAs may be inserted into replicable expression vehicles for expression of various IL-18BPs and viral IL-18BPs in host cells, according to the invention. DNAs capable of hybridizing to the above DNAs under stringent conditions and encoding proteins or polypeptides which are also capable of binding IL-18 are also included in the present invention.

One such DNA encodes an IL-18BP including the amino acid sequence of SEQ ID NO:10 and provided with a stop codon at its 3' end.

The expression vectors, suitable for expression of various IL-18BPs or viral IL-18BPs in humans and in other mammals, i.e. for gene therapy, may be viral vectors or other types of vectors in which an IL-18BP gene or an IL-18BP cDNA or a DNA encoding a viral IL-18BP was inserted in a way that enables efficient expression of an IL-18BP or a viral IL-18BP in humans and other mammals. DNA molecules hybridizing to the above DNAs under stringent conditions and encoding proteins or polypeptides which are capable of binding IL-18, are also included in the present invention.

Isolation of IL-18BP may be carried out in accordance with the invention, e.g. by passing a human fluid, such as urine or serum, through a chromatographic column to which IL-18 is coupled, and thereafter, eluting the bound IL-18BP.

The various IL-18BPs and viral IL-18BPs can also be prepared by recombinant means, i.e. by expressing IL-18BP in a suitable host, after operatively linking promoters, expression enhancers, regulatory sequences, etc., suitable for the particular host employed which e.g. allow expression in the correct orientation.

The various IL-18BPs and viral IL-18BPs and vectors for expressing IL-18BP in humans and other mammals may be employed in the treatment and alleviation of conditions in which IL-18 is involved or caused by an excess of exogenously administered or endogenously produced IL-18. Such conditions are, e.g., autoimmune diseases, type I diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart diseases (including heart attacks), ischemic brain injury, chronic hepatitis, psoriasis, chronic pancreatitis, acute pancreatitis and the like.

According to the present invention, IL-18BP was isolated from normal human urine by one chromatographic step. A preparation of crude human urinary proteins concentrated from 500l of normal human urine was loaded on a column consisting of human IL-18 bound to agarose. The column was washed and bound proteins were eluted at low pH. Eluted
 5 fractions were neutralized and aliquots were analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and silver staining. A protein band of ~40 kD was specifically obtained in the eluted fractions (Fig. 1).

The ~40 kD protein obtained in the first step was identified as an IL-18 binding protein by its ability to specifically cross-link with ¹²⁵I-IL-18 (Fig. 2). The ~40 kD protein
 10 was further characterized by N-terminal protein sequence analysis. Aliquots from the eluted protein were subjected to SDS-PAGE, electroblotted to a PVDF membrane and subjected to protein microsequence analysis. Similarly, aliquots from the eluted protein were subjected to direct protein microsequence analysis. In both cases, two polypeptide sequences were obtained. A major sequence and a minor sequence, the latter corresponding to a fragment of
 15 human defensin (accession number p11398), starting at amino acid 65. Subtraction of the known defensin sequence provided the following sequence:

T-P-V-S-Q-Q-x-x-x-A-A-A
 1 . . . 5 . . . 10 . .

wherein x represents a yet undetermined amino acid.

20 In order to obtain a longer and more accurate sequence and in order to identify potential cysteine residues, an aliquot of the eluted fraction was reduced with DTT under denaturing conditions, reacted with 4-vinyl pyridine, desalted by a micro-ultrafiltration device (Ultrafree, cutoff 10,000 Da, Millipore) and subjected to protein microsequence analysis. After sequencing cycle No. 1 the residual protein was reacted with o-phthalaldehyde
 25 to block all N-terminal polypeptides other than Pro and sequencing was then resumed. In this way the following single protein sequence was obtained:

TPVSQXXXAA XASVRSTKDP CPSQPPVFPA AKQCPALEVT
 1 10 20 30 40

30 (T=Thr; P=Pro; V=Val; S=Ser; Q=Gln; X=Unknown; A=Ala; R=Arg; K=Lys; D=Asp; C=Cys; F=Phe; L=Leu; E=Glu)

splenocytes, human peripheral blood mononuclear cells, the human KG-1 cell line and T-cells,

- (ii) enhancement of T-cell proliferation,
- (iii) enhancement of Th-1 cytokine production *in vitro*, primarily as a co-stimulant,
- 5 (iv) synergism with IL-12 in terms of enhanced IFN- γ production, co-stimulatory action for production of IFN- γ and other T-helper cell-1 cytokines,
- (v) co-stimulatory action for FAS ligand-mediated cytotoxicity of murine natural killer cell clones,
- 10 (vi) induction of the activation of NF- κ B in human KG-1 cells, probably by inducing the formation of the 50 NF- κ B homodimer and the p65/p50 NF- κ B heterodimer,
- (vii) induction of IL-8.

15 As used herein, the expression "binding to IL-18" means the capability of IL-18BP to bind IL-18, e.g. as evidenced by its binding to labeled IL-18 when affinity purified as in Example 2 herein.

As used herein, the expression "modulating the activity of IL-18" means the capability of IL-18BP to modulate any IL-18 activity other than blocking, e.g. partial
20 inhibition, enhancement, or the like.

As used herein, the expression "blocking the activity of IL-18" refers to the activity of IL-18BP to block at least one of the above exemplified biological activities of IL-18. The IL-18 blocking activity of IL-18BP is exemplified by the ability of IL-18BP to block the IL-18 associated IFN- γ expression in murine splenocytes. As it will be shown below in more
25 detail, the modulating or blocking activity of IL-18BP is in part due to the fact that IL-18BP inhibits the activation of NF- κ B by IL-18. Furthermore, IL-18BP blocks at least one of the following activities of IL-18, namely induction of IFN- γ in human and mouse cells, induction of IL-8 and activation of NF- κ B.

A DNA probe for screening cDNA libraries was prepared by reverse-transcription
30 PCR with specific sense and antisense primers and RNA from the human Jurkat T cells with primers from the TIGR sequence. The resulting PCR product was confirmed by DNA

sequence analysis. This PCR product was labeled with ^{32}P and used as a probe for screening of four human cDNA libraries, derived from peripheral blood monocytes, from the Jurkat T-cell line, from PBMC and from human spleen. The various independent cDNA clones corresponded to four IL-18BP splice variants (SEQ ID NO:1, 3, 5 and 7). All splice variants coded for putative soluble secreted proteins. The most abundant one (IL-18BP_a) had an open reading frame of 192 codons, coding for a signal peptide herein sometimes referred to as a "leader sequence" of 28 amino acid residues followed by a mature putative IL-18BP_a, whose first 40 residues matched perfectly with the N-terminal protein sequence of the urinary IL-18BP (SEQ ID NO:2). The position of the cysteine residues suggested that this polypeptide belongs to the immunoglobulin (Ig) super-family. Interestingly, each of the four Gln residues within mature IL-18BP_a was a potential N-glycosylation site. The three other variants of IL-18BP were less abundant than IL-18BP_a. They included a shorter 1 kb IL-18BP_b cDNA, coding for a signal peptide of 28 amino acid residues followed by a mature protein of 85 amino acid residues (SEQ ID NO:4). A third variant, IL-18BP_c was represented by a 2.3 kb cDNA, coding for a signal peptide of 28 amino acid residues followed by a mature IL-18BP of 169 amino acid residues (SEQ ID NO:6). The fourth variant, IL-18BP_d, coded for a signal peptide of 28 amino acid residues followed by a mature IL-18BP of 133 amino acid residues (SEQ ID NO:8).

To further study the possible existence of additional IL-18BP splice variants, a human genomic library was screened with a probe corresponding to full length IL-18BP cDNA. Five genomic clones, differing in length, were identified in this library. These clones were subjected to DNA sequence analysis with external and internal primers. Altogether, a 7.8 kb sequence was assembled from these clones (SEQ ID NO:9). No exon coding for a trans-membrane (TM) receptor was identified within the 7.8 kb sequence. All variants shared a common translation start site, coded for the same signal peptide of 28 amino acid residues and soluble mature proteins of varying sizes and C-terminal sequences. The IL-18BP locus contains an additional gene, coding for the nuclear mitotic apparatus protein 1 (NUMA1), positioned at the minus strand. This finding localizes the IL-18BP gene to human chromosome 11q13 (36).

An homology search was done with the complete protein sequence of IL-18BP_a and the GenPept database ([HTTP://www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)), using the Smith Watermann

algorithm. It was found that homologues of IL-18BP are expressed in several Poxviruses as secreted proteins of a previously unknown function. It was previously reported that viruses code for various cytokine receptors and that such virally encoded molecules serve as decoy receptors that inhibit immune responses by neutralizing their corresponding cytokine (reviewed by Spriggs, MK, 1994, *Curr. Opin. Immunol.*, 6, 526-529). Therefore the invention further relates to virally encoded homologues of IL-18BP that may also serve as blockers or modulators of the biological activity of IL-18. Examples of virus-encoded homologues of IL-18BP are provided in Table 1.

According to the present invention the virus encoded homologue of IL-18BP may be expressed in a prokaryotic or eukaryotic host. As used herein, the expression "virus encoded homologue IL-18BP" refers to a similarity of at least 50% in a sequence of at least 70 amino acid residues. More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% similarity thereto in a sequence of 100 amino acid residues.

Table 1. Virus-encoded proteins, showing high homology to human IL-18BP

GenPept sequence	Virus type
MCU60315_54	U60315 Molluscum contagiosum virus subtype 1
MCU60315_53	U60315 Molluscum contagiosum virus subtype 1
SWPHLSB_12	L22013 Swinepox virus
CV41KBPL_14	Cowpox virus
VVCGAA_5	Variola virus
U01161_3 174	Ectromelia virus (mouse Poxvirus)
VVU18340_6	Variola virus
VVU18338_7	Variola virus
VVU18337_7	Variola virus
VARCG_7 173	Variola major virus
MCU60315_51	Molluscum contagiosum virus
HNABV_1	New Hepatitis non-A, non-B associated virus

IL-18BP_a was expressed in monkey COS7 cells. For this purpose, the cDNA of IL-18BP_a was inserted into the mammalian expression vector pEF-BOS. A cassette coding for an (His)₆ sequence was added to the 3'-end of the IL-18BP ORFs in frame, in order to facilitate purification of the recombinant protein. COS7 cells were transiently transfected with the expression vector and serum-free medium of these cells (150 ml) was concentrated and purified by metal chelate chromatography. IL-18BP_a ran as a single band upon SDS-PAGE with silver staining under reducing and non-reducing conditions and had the same apparent molecular mass as that of the urinary IL-18BP. Protein sequence analysis of this preparation revealed the same N-terminal sequence as that of the urinary IL-18BP. Immunoblot analysis of IL-18BP_a with antibodies raised against the urinary IL-18BP revealed the same molecular mass band as that of the urinary protein. Furthermore, using immunoprecipitation followed by SDS-PAGE and autoradiography, IL-18BP_a was able to displace urinary ¹²⁵I-IL-18BP from binding to the antibody. Therefore, IL-18BP_a corresponds structurally to the IL-18BP isolated from urine.

Crude and purified IL-18BP_a were tested for their ability to inhibit the biological activity of IL-18. IL-18BP_a inhibited the activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9). These results confirm the identity of IL-18BP_a cDNA as the one coding for a biologically active IL-18BP.

The invention further relates to muteins and fragments of IL-18BPs and viral IL-18BPs and to fused proteins consisting of wild type IL-18BPs and viral IL-18BPs or their muteins or their fragments, fused to another polypeptide or protein and being capable of binding IL-18 or its homologues.

As used herein the term "muteins" refers to analogs of an IL-18BP, or analogs of a viral IL-18BP, in which one or more of the amino acid residues of a natural IL-18BP or viral IL-18BP are replaced by different amino acid residues, or are deleted, or one or more amino acid residues are added to the natural sequence of an IL-18BP, or a viral IL-18BP, without changing considerably the capability of the resulting products as compared with the wild type IL-18BP or viral IL-18BP to bind to IL-18. These muteins are prepared by known synthesis and/or by site-directed mutagenesis techniques, or any other known technique suitable therefor.

Any such mutein preferably has a sequence of amino acids sufficiently duplicative of that of an IL-18BP, or sufficiently duplicative of a viral IL-18BP, such as to have substantially similar activity to IL-18BP. One activity of IL-18BP is its capability of binding IL-18. As long as the mutein has substantial binding activity to IL-18, it can be used in the purification of IL-18, such as by means of affinity chromatography, and thus can be considered to have substantially similar activity to IL-18BP. Thus, it can be determined whether any given mutein has substantially the same activity as IL-18BP by means of routine experimentation comprising subjecting such a mutein, *e.g.*, to a simple sandwich competition assay to determine whether or not it binds to an appropriately labeled IL-18, such as radioimmunoassay or ELISA assay.

In a preferred embodiment, any such mutein has at least 40% identity or homology with the sequence of either an IL-18BP or a virally-encoded IL-18BP homologue. More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% identity or homology thereto.

Muteins of IL-18BP polypeptides or muteins of viral IL-18BPs, which can be used in accordance with the present invention, or nucleic acid coding therefor, include a finite set of substantially corresponding sequences as substitution peptides or polynucleotides which can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. For a detailed description of protein chemistry and structure, see Schulz, G.E. et al., *Principles of Protein Structure*, Springer-Verlag, New York, 1978; and Creighton, T.E., *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, 1983, which are hereby incorporated by reference. For a presentation of nucleotide sequence substitutions, such as codon preferences, see Ausubel et al, *supra*, at §§ A.1.1-A.1.24, and Sambrook et al, *supra*, at Appendices C and D.

Preferred changes for muteins in accordance with the present invention are what are known as "conservative" substitutions. Conservative amino acid substitutions of IL-18BP polypeptides or proteins or viral IL-18BPs, may include synonymous amino acids within a group which have sufficiently similar physicochemical properties that substitution between members of the group will preserve the biological function of the molecule, Grantham, *Science*, Vol. 185, pp. 862-864 (1974). It is clear that insertions and deletions of amino acids

may also be made in the above-defined sequences without altering their function, particularly if the insertions or deletions only involve a few amino acids, *e.g.*, under thirty, and preferably under ten, and do not remove or displace amino acids which are critical to a functional conformation, *e.g.*, cysteine residues, Anfinsen, "Principles That Govern The Folding of Protein Chains", Science, Vol. 181, pp. 223-230 (1973). Proteins and muteins produced by such deletions and/or insertions come within the purview of the present invention.

However, cysteine residues which are not required for biological activity may be replaced with other residues, *e.g.* in order to avoid the formation of undesired intramolecular or intermolecular disulfide bridges which may cause a reduction in the activity of the IL-18BPs.

Preferably, the synonymous amino acid groups are those defined in Table I. More preferably, the synonymous amino acid groups are those defined in Table II; and most preferably the synonymous amino acid groups are those defined in Table III.

15

20

25

30

TABLE I**Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
	Ser	Ser, Thr, Gly, Asn
5	Arg	Arg, Gln, Lys, Glu, His
	Leu	Ile, Phe, Tyr, Met, Val, Leu
	Pro	Gly, Ala, Thr, Pro
	Thr	Pro, Ser, Ala, Gly, His, Gln, Thr
	Ala	Gly, Thr, Pro, Ala
10	Val	Met, Tyr, Phe, Ile, Leu, Val
	Gly	Ala, Thr, Pro, Ser, Gly
	Ile	Met, Tyr, Phe, Val, Leu, Ile
	Phe	Trp, Met, Tyr, Ile, Val, Leu, Phe
	Tyr	Trp, Met, Phe, Ile, Val, Leu, Tyr
15	Cys	Ser, Thr, Cys
	His	Glu, Lys, Gln, Thr, Arg, His
	Gln	Glu, Lys, Asn, His, Thr, Arg, Gln
	Asn	Gln, Asp, Ser, Asn
	Lys	Glu, Gln, His, Arg, Lys
20	Asp	Glu, Asn, Asp
	Glu	Asp, Lys, Asn, Gln, His, Arg, Glu
	Met	Phe, Ile, Val, Leu, Met
	Trp	Trp
25		
30		

TABLE II**More Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
	Ser	Ser
5	Arg	His, Lys, Arg
	Leu	Leu, Ile, Phe, Met
	Pro	Ala, Pro
	Thr	Thr
	Ala	Pro, Ala
10	Val	Val, Met, Ile
	Gly	Gly
	Ile	Ile, Met, Phe, Val, Leu
	Phe	Met, Tyr, Ile, Leu, Phe
	Tyr	Phe, Tyr
15	Cys	Cys, Ser
	His	His, Gln, Arg
	Gln	Glu, Gln, His
	Asn	Asp, Asn
	Lys	Lys, Arg
20	Asp	Asp, Asn
	Glu	Glu, Gln
	Met	Met, Phe, Ile, Val, Leu
	Trp	Trp

TABLE III**Most Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
	Ser	Ser
5	Arg	Arg
	Leu	Leu, Ile, Met
	Pro	Pro
	Thr	Thr
	Ala	Ala
10	Val	Val
	Gly	Gly
	Ile	Ile, Met, Leu
	Phe	Phe
	Tyr	Tyr
15	Cys	Cys, Ser
	His	His
	Gln	Gln
	Asn	Asn
	Lys	Lys
20	Asp	Asp
	Glu	Glu
	Met	Met, Ile, Leu
	Trp	Met

25 Examples of production of amino acid substitutions in proteins which can be used for obtaining muteins of IL-18BP polypeptides or proteins, or muteins of viral IL-18BPs, for use in the present invention include any known method steps, such as presented in US patents RE 33,653, 4,959,314, 4,588,585 and 4,737,462, to Mark et al; 5,116,943 to Koths et al., 4,965,195 to Namen et al; 4,879,111 to Chong et al; and 5,017,691 to Lee et al; and lysine

30 substituted proteins presented in US patent No. 4,904,584 (Shaw et al).

In another preferred embodiment of the present invention, any mutein of an IL-18BP or a viral IL-18BP, has an amino acid sequence essentially corresponding to that of an IL-18BP, or to a viral IL-18BP. The term "essentially corresponding to" is intended to comprehend proteins with minor changes to the sequence of the natural protein which do not affect the basic characteristics of the natural proteins, particularly insofar as their ability to bind IL-18. The type of changes which are generally considered to fall within the "essentially corresponding to" language are those which would result from conventional mutagenesis techniques of the DNA encoding these proteins, resulting in a few minor modifications, and screening for the desired activity in the manner discussed above. In addition to binding IL-18, the muteins may also modulate and/or block IL-18 activity.

Muteins in accordance with the present invention include proteins encoded by a nucleic acid, such as DNA or RNA, which hybridizes to DNA or RNA, which encodes an IL-18BP or encodes a viral IL-18BP, in accordance with the present invention, under stringent conditions. The invention also includes such nucleic acid, which is also useful as a probe in identification and purification of the desired nucleic acid. Furthermore, such nucleic acid would be a prime candidate to determine whether it encodes a polypeptide, which retains the functional activity of an IL-18BP of the present invention. The term "stringent conditions" refers to hybridization and subsequent washing conditions, which those of ordinary skill in the art conventionally refer to as "stringent". See Ausubel et al., Current Protocols in Molecular Biology, *supra*, Interscience, N.Y., §§6.3 and 6.4 (1987, 1992), and Sambrook et al., *supra*. Without limitation, examples of stringent conditions include washing conditions 12-20°C below the calculated T_m of the hybrid under study in, e.g., 2 x SSC and 0.5% SDS for 5 minutes, 2 x SSC and 0.1% SDS for 15 minutes; 0.1 x SSC and 0.5% SDS at 37°C for 30-60 minutes and then, a 0.1 x SSC and 0.5% SDS at 68°C for 30-60 minutes. Those of ordinary skill in this art understand that stringency conditions also depend on the length of the DNA sequences, oligonucleotide probes (such as 10-40 bases) or mixed oligonucleotide probes. If mixed probes are used, it is preferable to use tetramethyl ammonium chloride (TMAC) instead of SSC. See Ausubel, *supra*.

The invention further includes nucleic acids which code for IL-18BP according to the present invention, but which differ in codon sequence due to the degeneracy of the genetic

code. Such a DNA which possibly does not hybridize under stringent conditions to the DNA sequences shown in Figures 4 to 7, but is nevertheless capable of encoding an IL-18BP according to the present invention is also included by the invention.

The term "fused protein" refers to a polypeptide comprising an IL-18BP, or a viral
5 IL-18BP, or a mutein thereof, fused with another protein, which, *e.g.*, has an extended residence time in body fluids. An IL-18BP or a viral IL-18BP, may thus be fused to another protein, polypeptide or the like, *e.g.*, an immunoglobulin or a fragment thereof. It may also be fused to polyethylene glycol (PEG) in order to prolong residence time.

The term "salts" herein refers to both salts of carboxyl groups and to acid addition
10 salts of amino groups of an IL-18BP, a viral IL-18BP, muteins, or fused proteins thereof. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example,
15 salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid. Of course, any such salts must have substantially similar activity to IL-18BP.

"Functional derivatives" as used herein cover derivatives of IL-18BPs or a viral
20 IL-18BP, and their muteins and fused proteins, which may be prepared *e.g.* from the functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, *i.e.* they do not destroy the activity of the protein which is substantially similar to the activity of IL-18BP, or viral IL-18BPs, and do not confer toxic properties on compositions containing it. These derivatives may, for example, include
25 polyethylene glycol side-chains, which may mask antigenic sites and extend the residence of an IL-18BP or a viral IL-18BP in body fluids. Other derivatives include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino groups of the amino acid residues formed with acyl moieties (*e.g.* alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of

free hydroxyl groups (for example that of seryl or threonyl residues) formed with acyl moieties.

As "active fractions" of an IL-18BP, or a viral IL-18BP, muteins and fused proteins, the present invention covers any fragment or precursors of the polypeptide chain of the protein molecule alone or together with associated molecules or residues linked thereto, *e.g.*,
5 sugar or phosphate residues, or aggregates of the protein molecule or the sugar residues by themselves, provided said fraction substantially retains the capability of binding IL-18.

The term "circularly permuted derivatives" as used herein refers to a linear molecule in which the termini have been joined together, either directly or through a linker, to produce
10 a circular molecule, and then the circular molecule is opened at another location to produce a new linear molecule with termini different from the termini in the original molecule. Circular permutations include those molecules whose structure is equivalent to a molecule that has been circularized and then opened. Thus, a circularly permuted molecule may be synthesized
de novo as a linear molecule and never go through a circularization and opening step. The
15 preparation of circularly permuted derivatives is described in WO95/27732.

Various recombinant cells such as prokaryotic cells, *e.g.*, *E. coli*, or other eukaryotic cells, such as yeast or insect cells can produce IL-18BPs or viral IL-18BPs. Methods for constructing appropriate vectors, carrying DNA that codes for an IL-18BP and suitable for transforming (*e.g.*, *E. coli*, mammalian cells and yeast cells), or infecting insect cells in order
20 to produce a recombinant IL-18BP or a viral IL-18BP are well known in the art. See, for example, Ausubel et al., eds. "Current Protocols in Molecular Biology" Current Protocols, 1993; and Sambrook et al., eds. "Molecular Cloning: A Laboratory Manual", 2nd ed., Cold Spring Harbor Press, 1989.

For the purposes of expression of IL-18BP proteins, or viral IL-18BPs, DNA
25 encoding an IL-18BP or a viral IL-18BP, their fragments, muteins or fused proteins, and the operably linked transcriptional and translational regulatory signals, are inserted into vectors which are capable of integrating the desired gene sequences into the host cell chromosome. In order to be able to select the cells which have stably integrated the introduced DNA into their chromosomes, one or more markers which allow for selection of host cells which
30 contain the expression vector is used. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, *e.g.*, antibiotics, or resistance to heavy metals, such as

copper, or the like. The selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by cotransfection. Additional elements may also be needed for optimal synthesis of single chain binding protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals.

Said DNA molecule to be introduced into the cells of choice will preferably be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Preferred prokaryotic plasmids are derivatives of pBr322. Preferred eukaryotic vectors include BPV, vaccinia, SV40, 2-micron circle, etc., or their derivatives. Such plasmids and vectors are well known in the art (2-5, 22). Once the vector or DNA sequence containing the construct(s) has been prepared for expression, the expression vector may be introduced into an appropriate host cell by any of a variety of suitable means, such as transformation, transfection, lipofection, conjugation, protoplast fusion, electroporation, calcium phosphate precipitation, direct microinjection, etc.

Host cells to be used in this invention may be either prokaryotic or eukaryotic. Preferred prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, etc. The most preferred prokaryotic host is E. coli. Bacterial hosts of particular interest include E. coli K12 strain 294 (ATCC 31446), E. coli X1776 (ATCC 31537), E. coli W3110 (F⁻, lambda⁻, phototropic (ATCC 27325). Under such conditions, the protein will not be glycosylated. The prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

However, since natural IL-18BPs are glycosylated proteins, eukaryotic hosts are preferred over prokaryotic hosts. Preferred eukaryotic hosts are mammalian cells, e.g., human, monkey, mouse and Chinese hamster ovary (CHO) cells, because they provide post-translational modifications to protein molecules including correct folding, correct disulfide bond formation, as well as glycosylation at correct sites. Also yeast cells and insect cells can carry out post-translational peptide modifications including high mannose glycosylation.

A number of recombinant DNA strategies exist which utilize strong promoter sequences and high copy number of plasmids, which can be utilized for production of the desired proteins in yeast and in insect cells. Yeast and insect cells recognize leader sequences

on cloned mammalian gene products and secrete mature IL-18BP. After the introduction of the vector, the host cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of an IL-18BP, a viral IL-18BP, fusion proteins, or muteins or fragments thereof. The
5 above-mentioned cloning, clone isolation, identification, characterization and sequencing procedures are described in more detail hereinafter in the Examples.

The expressed proteins are then isolated and purified by any conventional procedure involving extraction, precipitation, chromatography, electrophoresis, or the like, or by
10 affinity chromatography, using, e.g., an anti-IL-18BP monoclonal antibodies immobilized on a gel matrix contained within a column. Crude preparations containing said recombinant IL-18BP are passed through the column whereby IL-18BP will be bound to the column by the specific antibody, while the impurities will pass through. After washing, the protein is eluted from the gel under conditions usually employed for this purpose, *i.e.* at a high or a low
15 pH, *e.g.* pH 11 or pH 2.

The invention further relates to vectors useful for expression of an IL-18BP or a viral IL-18BP or their derivatives in mammals and more specifically in humans. Vectors for short and long-term expression of genes in mammals are well known in the literature. Studies have shown that gene delivery to *e.g.*, skeletal muscle, vascular smooth muscle and liver result in
20 systemic levels of therapeutic proteins. Skeletal muscle is a useful target because of its large mass, vascularity and accessibility. However, other targets and particularly bone marrow precursors of immune cells have been used successfully. Currently available vectors for expression of proteins in *e.g.*, muscle include plasmid DNA, liposomes, protein-DNA conjugates and vectors based on adenovirus, adeno-associated virus and herpes virus. Of
25 these, vectors based on adeno-associated virus (AAV) have been most successful with respect to duration and levels of gene expression and with respect to safety considerations (Kessler, P.D. 1996, Proc. Natl. Acad. Sci. USA 93, 14082-14087).

Procedures for construction of an AAV-based vector have been described in detail (Snyder et al, 1996, Current Protocols in Human Genetics, Chapters 12.1.1-12.1.17, John
30 Wiley & Sons) and are incorporated into this patent. Briefly plasmid psub201, containing the wild-type AAV genome is cut with the restriction enzyme Xba I and ligated with a construct

consisting of an efficient eukaryotic promoter, e.g., the cytomegalovirus promoter, a Kozak consensus sequence, a DNA sequence coding for an IL-18BP or a viral IL-18BP, or their muteins or fusion proteins or fragments thereof, a suitable 3' untranslated region and a polyadenylation signal, e.g., the polyadenylation signal of simian virus 40. The resulting
5 recombinant plasmid is cotransfected with an helper AAV plasmid e.g., pAAV/Ad into mammalian cells e.g., human T293 cells. The cultures are then infected with adenovirus as a helper virus and culture supernatants are collected after 48-60 hours. The supernatants are fractionated by ammonium sulfate precipitation, purified on a CsCl density gradient, dialyzed and then heated at 56°C to destroy any adenovirus, whereas the resulting
10 recombinant AAV, capable of expressing IL-18BP or a viral IL-18BP, or their muteins or fusion proteins remains stable at this step.

So far, the physiological role of the soluble cytokine receptors has not been established. The soluble receptors bind their specific ligands and in most cases inhibit their biological activity, as was shown, e.g., in the TNF system (11, 12). In very few cases, e.g.,
15 IL-6, the soluble receptor enhances the biological activity. The recombinant soluble TNF receptor, also known as TBP (TNF binding protein) was found to prevent septic shock in animal models, while soluble forms of IL-1 receptor were found to have profound inhibitory effects on the development of in vivo alloreactivity in mouse allograft recipients.

Similarly, the IL-18BPs and viral IL-18BPs of the present invention may find use as
20 modulators of IL-18 activity, e.g. in type I diabetes, in sepsis, in autoimmune diseases, in graft rejections, rheumatoid arthritis, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease including acute heart attacks, ischemic brain injury, chronic hepatitis, psoriasis, chronic hepatitis and acute hepatitis. They may thus be used, e.g. in any disease in which endogenous production or exogenous administration of IL-18 induces the disease or
25 aggravates the situation of the patient.

The present invention further relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an IL-18BP or a viral IL-18BP of the invention or their active muteins, fused proteins and their salts, functional derivatives or active fractions thereof.

30 The present invention further relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and e.g., a viral vector such as any one of said

AAV-based viral vectors or another vector expressing an IL-18BP or viral IL-18BP or their muteins, fragments or fusion proteins thereof and suitable for administration to humans and other mammals for the purpose of attaining expression in vivo of IL-18BP or a viral IL-18BP or their muteins or fragments or fusion protein of the invention, i.e. for use in gene therapy.

5 The pharmaceutical compositions of the invention are prepared for administration by mixing an IL-18BP or a viral IL-18BP, or their derivatives, or vectors for expressing same with physiologically acceptable carriers, and/or stabilizers and/or excipients, and prepared in dosage form, e.g., by lyophilization in dosage vials. The method of administration can be via any of the accepted modes of administration for similar agents and will depend on the
10 condition to be treated, e.g., intravenously, intramuscularly, subcutaneously, by local injection or topical application, or continuously by infusion, etc. The amount of active compound to be administered will depend on the route of administration, the disease to be treated and the condition of the patient. Local injection, for instance, will require a lower amount of the protein on a body weight basis than will intravenous infusion.

15 Accordingly, IL-18BPs, or viral IL-18BPs, or vectors expressing same in vivo are indicated for the treatment of autoimmune diseases, Type I diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease including acute heart attacks, ischemic brain injury, chronic hepatitis, psoriasis, chronic pancreatitis and acute pancreatitis and similar diseases, in which there is an aberrant
20 expression of IL-18, leading to an excess of IL-18 or in cases of complications due to exogenously administered IL-18.

The invention also includes antibodies against an IL-18BP or a viral IL-18BP, as well as against their muteins, fused proteins, salts, functional derivatives and active fractions. The term "antibody" is meant to include polyclonal antibodies, monoclonal antibodies (MAbs),
25 chimeric antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, and humanized antibodies as well as fragments thereof provided by any known technique, such as, but not limited to enzymatic cleavage, peptide synthesis or recombinant techniques.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen. A monoclonal antibody contains a substantially homogeneous population of antibodies specific to antigens, which population contains substantially similar epitope binding sites. MAbs may be obtained by methods
5 known to those skilled in the art. See, for example Kohler and Milstein, Nature 256:495-497 (1975); US Patent No. 4,376,110; Ausubel et al, eds., supra, Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor Laboratory (1988); and Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), the contents of which references are incorporated entirely
10 herein by reference. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof. A hybridoma producing a MAb of the present invention may be cultivated *in vitro*, *in situ* or *in vivo*. Production of high titers of MAbs *in vivo* or *in situ* makes this the presently preferred method of production.

Chimeric antibodies are molecules, different portions of which are derived from
15 different animal species, such as those having the variable region derived from a murine MAb and a human immunoglobulin constant region. Chimeric antibodies are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine MAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric MAbs are used. Chimeric antibodies and methods
20 for their production are known in the art (Cabilly et al, Proc. Natl. Acad. Sci. USA 81:3273-3277 (1984); Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984); Boulianne et al., Nature 312:643-646 (1984); Cabilly et al., European Patent Application 125023 (published November 14, 1984); Neuberger et al., Nature 314:268-270 (1985); Taniguchi et al., European Patent Application 171496 (published February 19, 1985);
25 Morrison et al., European Patent Application 173494 (published March 5, 1986); Neuberger et al., PCT Application WO 8601533, (published March 13, 1986); Kudo et al., European Patent Application 184187 (published June 11, 1986); Morrison et al., European Patent Application 173494 (published March 5, 1986); Sahagan et al., J. Immunol. 137:1066-1074 (1986); Robinson et al., International Patent Publication, WO 9702671 (published 7 May
30 1987); Liu et al., Proc. Natl. Acad. Sci. USA 84:3439-3443 (1987); Sun et al., Proc. Natl.

Acad. Sci. USA 84:214-218 (1987); Better et al., Science 240:1041- 1043 (1988); and Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, supra. These references are entirely incorporated herein by reference.

An anti-idiotypic (anti-Id) antibody is an antibody, which recognizes unique
5 determinants generally, associated with the antigen-binding site of an antibody. An Id antibody can be prepared by immunizing an animal of the same species and genetic type (e.g., mouse strain) as the source of the MAb with the MAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the
10 anti-Id antibody). See, for example, US patent No. 4,699,880, which is herein entirely incorporated by reference.

The anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody. The anti-anti-Id may be epitopically identical to the original MAb, which induced the anti-Id. Thus, by using
15 antibodies to the idiotypic determinants of a MAb, it is possible to identify other clones expressing antibodies of identical specificity.

Accordingly, MAbs generated against IL-18BP and related proteins of the present invention may be used to induce anti-Id antibodies in suitable animals, such as BALB/c mice. Spleen cells from such immunized mice are used to produce anti-Id hybridomas
20 secreting anti-Id MAbs. Further, the anti-Id MAbs can be coupled to a carrier such as keyhole limpet hemocyanin (KLH) and used to immunize additional BALB/c mice. Sera from these mice will contain anti-anti-Id antibodies that have the binding properties of the original MAb specific for an IL-18BP epitope or epitopes of a viral IL-18BP.

The anti-Id MAbs thus have their own idiotypic epitopes, or "idiotopes" structurally
25 similar to the epitope being evaluated, such as an IL-18BP or a viral IL-18BP.

The term "humanized antibody" is meant to include e.g. antibodies which were obtained by manipulating mouse antibodies through genetic engineering methods so as to be more compatible with the human body. Such humanized antibodies have reduced

immunogenicity and improved pharmacokinetics in humans. They may be prepared by techniques known in the art, such as described, e.g. for humanized anti-TNF antibodies in *Molecular Immunology*, Vol. 30, No. 16, pp. 1443-1453, 1993.

The term "antibody" is also meant to include both intact molecules as well as
5 fragments thereof, such as, for example, Fab and F(ab')₂, which are capable of binding antigen. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983)). It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies useful in the present invention may be used for
10 the detection and quantitation of an IL-18BP or a viral IL-18BP, according to the methods disclosed herein for intact antibody molecules. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments).

An antibody is said to be "capable of binding" a molecule if it is capable of
15 specifically reacting with the molecule to thereby bind the molecule to the antibody. The term "epitope" is meant to refer to that portion of any molecule capable of being bound by an antibody which can also be recognized by that antibody. Epitopes or "antigenic determinants" usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural
20 characteristics as well as specific charge characteristics.

An "antigen" is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. An antigen may have one or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a
25 highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

The antibodies, including fragments of antibodies, useful in the present invention may be used to detect quantitatively or qualitatively an IL-18BP or a viral IL-18BP, or

related proteins in a sample or to detect presence of cells, which express such proteins of the present invention. This can be accomplished by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorometric detection.

5 The antibodies (or fragments thereof) useful in the present invention may be employed histologically, as in immunofluorescence or immunoelectron microscopy, for *in situ* detection of an IL-18BP or a viral IL-18BP, and related proteins of the present invention. *In situ* detection may be accomplished by removing a histological specimen from a patient, and providing the a labeled antibody of the present invention to such a specimen. The
10 antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of an IL-18BP or a viral IL-18BP, or related proteins but also its distribution on the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of wide variety of histological methods (such as
15 staining procedures) can be modified in order to achieve such *in situ* detection.

Such assays for an IL-18BP or a viral IL-18BP, or related proteins of the present invention typically comprises incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells such as lymphocytes or leukocytes, or cells which have been incubated in tissue culture, in the presence of a detectably labeled antibody capable of
20 identifying IL-18BP or related proteins, and detecting the antibody by any of a number of techniques well-known in the art.

The biological sample may be treated with a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins. The support or carrier may then be washed with suitable buffers
25 followed by treatment with a detectably labeled antibody in accordance with the present invention. The solid phase support or carrier may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on said solid support or carrier may then be detected by conventional means.

By "solid phase support", "solid phase carrier", "solid support", "solid carrier", "support" or "carrier" is intended any support or carrier capable of binding antigen or antibodies. Well-known supports or carriers, include glass, polystyrene, polypropylene, polyethylene, dextran, nylon amyloses, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support or carrier configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports or carriers include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of antibody in accordance with the present invention may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.

One of the ways in which an antibody in accordance with the present invention can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA). This enzyme, in turn, when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha- glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6- phosphate dehydrogenase,

glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods, which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

5 Detection may be accomplished using any of a variety of other immunoassays. For example, by radioactivity labeling the antibodies or antibody fragments, it is possible to detect an IL-18BP or a viral IL-18BP, through the use of a radioimmunoassay (RIA). A good description of RIA maybe found in Laboratory Techniques and Biochemistry in Molecular Biology, by Work, T.S. et al., North Holland Publishing Company, NY (1978) with
10 particular reference to the chapter entitled "An Introduction to Radioimmuno Assay and Related Techniques" by Chard, T., incorporated by reference herein. The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

 It is also possible to label an antibody in accordance with the present invention with a
15 fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can be then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

 The antibody can also be detectably labeled using fluorescence emitting metals such
20 as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (ETPA).

 The antibody can also be detectably labeled by coupling it to biotin. Biotinylated antibody can then be detected by avidin or streptavidin coupled to a fluorescent compound or to an enzyme such as peroxidase or to a radioactive isotope and the like.

25 The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.

Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, therromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

An antibody molecule of the present invention may be adapted for utilization in a immunometric assay, also known as a "two-site" or "sandwich" assay. In a typical immunometric assay, a quantity of unlabeled antibody (or fragment of antibody) is bound to a solid support or carrier and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.

Typical, and preferred, immunometric assays include "forward" assays in which the antibody bound to the solid phase is first contacted with the sample being tested to extract the antigen from the sample by formation of a binary solid phase antibody-antigen complex. After a suitable incubation period, the solid support or carrier is washed to remove the residue of the fluid sample, including unreacted antigen, if any, and then contacted with the solution containing an unknown quantity of labeled antibody (which functions as a "reporter molecule"). After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support or carrier through the unlabeled antibody, the solid support or carrier is washed a second time to remove the unreacted labeled antibody.

In another type of "sandwich" assay, which may also be useful with the antigens of the present invention, the so-called "simultaneous" and "reverse" assays are used. A "simultaneous" assay involves a single incubation step as the antibody bound to the solid support or carrier and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support or carrier is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody

associated with the solid support or carrier is then determined as it would be in a conventional "forward" sandwich assay.

5 In the "reverse" assay, stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support or carrier after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support or carrier is then determined as in the "simultaneous" and "forward" assays.

10 The present invention also provides DNA molecules encoding any of the proteins of the present invention as defined above, replicable expression vehicles comprising any such DNA molecules, host cells transformed with any such expression vehicles including prokaryotic and eukaryotic and host cells, preferably CHO cells. The invention also includes a process for the production of expression vectors coding for any of the proteins of the present invention for the purpose of their expression in humans and other mammals.

The invention also includes a process for the production of any of the proteins of the present invention by culturing a transformed cell in accordance with the present invention and recovering the protein encoded by the DNA molecule and the expression vehicle within such transformed host cell.

20 In addition to the use of an IL-18BP or a viral IL-18BP, in modulating the activity of IL-18, they can, of course, also be employed for the purification of IL-18 itself. For this purpose, IL-18BP or a viral IL-18BP is coupled to an affinity column and crude IL-18 is passed through. The IL-18 can then be recovered from the column by, *e.g.*, elution at low pH.

The invention will now be illustrated by the following non-limiting examples:

25

EXAMPLE 1: Isolation of an IL-18 binding protein

E. coli IL-18 (2.5 mg, Peprotech, NJ) was coupled to Affigel-10 (0.5 ml, BioRad), according to the manufacturer's instructions and packed into a column. Crude urinary proteins (1000-fold concentrated, 500 ml) were loaded onto the column at a flow rate of 0.25
5 ml/min. The column was washed with 250 ml 0.5M NaCl in phosphate buffered saline (PBS). Bound proteins were then eluted with 25 mM citric acid, pH 2.2 and benzamidine (1 mM), immediately neutralized by 1M Na₂CO₃. Fractions of 1 ml were collected. The fractions were analyzed by SDS-PAGE and silver staining. The IL-18 binding protein eluted
10 IL-18BP exhibited a distinct yellow color upon silver staining. The various fractions were analyzed by cross-linking with ¹²⁵I-IL-18, SDS-PAGE and autoradiography as described in Example 2. An IL-18 binding protein was found in fractions 2-8, eluted from the IL-18-agarose column (Fig. 2).

EXAMPLE 2: Cross-linking of affinity-purified IL-18BP to labeled IL-18.

15 Samples (40 μl) of IL-18BP from the affinity purification step were incubated (70 min. at 4°C) with ¹²⁵I-IL-18 (5,000,000 cpm). Disuccinimidyl suberate (DSS), dissolved in dimethyl sulfoxide (Me₂SO, 20 mM), was then added to a final concentration of 2 mM and the mixture was left for 20 min. at 4°C. The reaction was stopped by the addition of 1M Tris-HCl pH 7.5, and 1M NaCl to a final concentration of 100 mM. A sample buffer
20 containing Dithiothreitol (DTT, 25 mM final) was added and the mixtures were analyzed by SDS-PAGE (7.5 % acrylamide) followed by autoradiography (Fig. 2).

A specific band of molecular weight 58 kD, probably consisting of a ~40 kD protein cross-linked to the ~20 kD ¹²⁵I-IL-18, was observed in fractions eluted from the IL-18 affinity column (lanes 2 and 3) but not in the column wash (lane 1), containing all other
25 crude urinary proteins.

EXAMPLE 3: Protein sequence analysis.

Eluted fractions from the affinity column of Example 1 were resolved by SDS-PAGE (10% acrylamide) under non-reducing conditions, electroblotted on a PVDF membrane (Pro-Blot, Applied Biosystems, USA). The membrane was stained with coomassie blue, the

5 ~40 kD band was excised and subjected to protein sequence analysis by a Procise microsequencer (Applied Biosystems, USA). The following major sequence was obtained:

T-P-V-S-Q-Q-x-x-x-A-A-A

1 . . . 5 . . . 10 . .

wherein x represents a yet undetermined amino acid.

10 In addition, a minor sequence was obtained:

A-x-Y-x-R-I-P-A-x-A-I-A

1 . . . 5 . . . 10 . .

Because of this double sequence it was not possible to obtain a longer sequence data.

15 The minor sequence was identified as a fragment of human defensin, (accession No. p11398) starting at amino acid 65 of defensin. The major sequence could not be associated with any other known protein, as determined by searching all available databases in NCBI and TIGR by the blastp and tblastn search programs.

In order to obtain a longer and more accurate sequence and in order to identify

20 potential cysteine residues, another aliquot of the fraction eluted from the IL-18-agarose column was reduced with DTT in 6 M guanidine HCl, reacted with 4-vinyl pyridine, desalted by a micro-ultrafiltration device (Ultrafree, cutoff 10,000 Daltons, Millipore) and subjected to protein microsequence analysis. After cycle No. 1 of sequencing, the filter was reacted with o-phtalaldehyde to block all N-terminal polypeptides other than Pro. In this way only

25 the major sequence was obtained as follows:

TPVSQXXXAA XASVRSTKDP CPSQPPVFPA AKQCPALEVT

1 10 20 30 40

30 (T=Thr; P=Pro; V=Val; S=Ser; Q=Gln; X=Unknown; A=Ala; R=Arg; K=Lys; D=Asp; C=Cys; F=Phe; L=Leu; E=Glu)

New bands, corresponding to 30 kD (just above the PNGase band) and 20 kD were obtained. The elimination of the ~40 kD band indicates that this band is an N-glycosylated protein.

EXAMPLE 5: Blocking of the biological activity of IL-18 by IL-18BP.

The ability of the IL-18BP isolated from urine to block IL-18 activity was determined
5 by measuring the IL-18-induced production of IFN- γ in mononuclear cells. IL-18 induces
IFN- γ when added together with either low concentration of LPS, IL-12, IL-2, or other
stimulants. The activity of IL-18 was tested in murine splenocytes, in human peripheral
blood mononuclear cells (PBMC) and in the human KG-1 cell line. Spleen cells were
prepared from a healthy mouse, washed and suspended in RPMI 1640 medium supplemented
10 with 10% fetal bovine serum at 5×10^6 cells/ml. 1.0 ml cultures were stimulated with LPS
(either 0.5 or 1 $\mu\text{g/ml}$) together with recombinant human or murine IL-18 (either 0.5 or 5
ng/ml). Human IL-18 binding protein (0, 5 or 50 ng/ml) was added to the recombinant IL-18
before adding to spleen cells. After culturing for 24h, the spleen cells were subjected to three
freeze (-70°C) and thaw (room temperature) cycles, the cellular debris was removed by
15 centrifugation and the supernatants were assayed for IFN- γ using the ELISA kits for mouse
IFN- γ (Endogen). As shown in Fig. 3A, IL-18BP blocked the activity of huIL-18 in murine
splenocytes in a dose-dependent manner. In contrast, as a control, soluble interferon- α/β
receptor had no effect. The activity of recombinant murine IL-18 was similarly inhibited by
the human IL-18BP, suggesting that human IL-18BP recognizes murine IL-18 (Fig. 3B).
20 Endogenous IL-18 is induced in murine splenocytes by high concentrations of LPS, leading
to production of IFN- γ . Indeed, IFN- γ induction by LPS (10 $\mu\text{g/ml}$) was also inhibited by the
urinary IL-18BP (Fig. 3C). Concanavalin A (con A) activates T-cells to produce IFN- γ in the
absence of IL-18 (13). Indeed, induction of IFN- γ by Con A was not inhibited by IL-18BP
even at high concentrations (Fig. 3D). This observation demonstrated that IL-18BP was a
25 specific inhibitor of IL-18 bioactivity rather than a non-specific inhibitor of IFN- γ
production. IL-18BP also inhibited the activity of human IL-18 in human KG-1 cells induced
by a combination of IL-18 and TNF- α (Fig. 3E).

The above data demonstrate that urinary IL-18BP inhibits human as well as murine
IL-18 activity as measured by co-induction of IFN- γ in human and murine mononuclear cells.

The concentration of IL-18BP which reduced IL-18 activity by >90% was comparable to that of IL-18 itself, suggesting a high affinity interaction between these two proteins.

EXAMPLE 6: Isolation of cDNA clones coding for IL-18BP.

Total RNA from Jurkat T-cells (CRL 8163, American Type Culture Collection) was
5 reverse-transcribed with SuperScript RNase H⁻ reverse transcriptase (Gibco-BRL) and
random primers (Promega, Madison WI). The resulting cDNA fragments were then
amplified by PCR, using Taq DNA polymerase (Sigma) and primers corresponding to TIGR
clone THC123801 nucleotides 24-44 (sense) and 500-481 (reverse). The amplification was
done in 30 cycles of annealing (55°C, 2 min) and extension (70°C, 1 min). The resulting
10 PCR products were resolved by agarose (1%) gel electrophoresis, eluted and cloned into
pGEM-Teasy TA cloning vector (Promega). DNA from individual clones was sequenced
with T7 and SP6 primers.

The resulting 477 bp fragment was ³²P-labeled by random priming. This probe was
used for screening various human cDNA and genomic libraries. Duplicate nitrocellulose
15 filters were lifted and hybridized with the probe at 60°C in a buffer consisting of 6xSSC, 10x
Denhardt's solution, 0.1% SDS and 100 µg/ml Salmon sperm DNA. The filters were washed
and exposed overnight at -80°C to Kodak XAR film. Double positive clones were
plaque-purified. Plasmids were excised from the λpCEV9 clones and self-ligated. cDNA
clones from other libraries were isolated according to the manufacturer's instructions.
20 Automated DNA sequence analysis of the isolated clones was performed with Models 373A
and 377 sequencers (Applied Biosystems) using sense and antisense primers. Standard
protocols were used for these cloning procedures (33).

The following libraries were screened: a human monocyte cDNA library, constructed
in λpCEV9 cloning vector (15), kindly provided by T. Miki; a human Jurkat leukemic T-cell
25 cDNA library, a human peripheral blood leukocyte cDNA library and a human spleen cDNA
library, all from Clontech (Palo Alto, CA). A human placenta genomic library in lambda FIX
II vector was from Stratagene (La Jolla, CA).

All cDNA clones corresponded to four different IL-18BP splice variants were
obtained and characterized. All splice variants coded for putative soluble secreted proteins.

The most abundant one (IL-18BPa) had an open reading frame of 192 codons, coding for a signal peptide of 28 amino acid residues followed by a mature putative IL-18BPa, whose first 40 residues (SEQ ID NO:10) matched perfectly with the N-terminal protein sequence of the urinary IL-18BP (SEQ ID NO:2). The position of the cysteine residues suggested that this polypeptide belongs to the immunoglobulin (Ig) super-family. Each of the four Gln residues within mature IL-18BPa was a potential N-glycosylation site. The other three splice variants of IL-18BP were significantly less abundant.

Another 1 kb IL-18BPb cDNA coded for a mature protein of 85 amino acid residues (SEQ ID NO:4). A third variant, IL-18BPc, was represented by a 2.3 kb cDNA, coding for a mature IL-18BP of 169 amino acid residues (SEQ ID NO:6). The fourth variant, IL-18BPd coded for a mature IL-18BP of 133 amino acid residues (SEQ ID NO:8). In-exon splicing occurred at two sites along the pro-mRNA. These events and an additional 5' exon in IL-18BPd gave rise to 3 different 5' UTRs in the various cDNA clones. It is therefore quite possible that different IL-18BP variants may be generated in response to distinct transcription regulation signals.

No cDNA coding for a receptor with a transmembrane domain was found so far.

Example 7. Construction of a mammalian expression vector, production of recombinant IL-18BP, and evaluation of the biological activities of recombinant IL-18BP

The coding region of the IL-18BPa cDNA was amplified by PCR with the sense primer 5' TATATCTAGAGCCACCATGAGACACAACCTGGACACCA

and the reverse primer:

5' ATATCTAGATTAATGATGATGATGATGATGATGACCCTGCTGCTGTGGACTGC.

The PCR products were cut with Xba I and cloned into the Xba I site of the pEF-BOS expression vector (25), to yield pEF-BOS-IL-18BPa. The constructs were confirmed by DNA sequencing.

Batches of 6×10^7 COS7 cells in 1.4 ml TD buffer, containing pEF-BOS-IL-18BPa plasmid DNA (10 μ g) and DEAE-dextran (120 μ g) were incubated for 30 min at room

temperature, as described (35). The cells were then washed with DMEM -10% FBS, plated for 4 hr in DMEM-10, washed and incubated for 3-5 days in serum-free DMEM. Culture medium was collected, concentrated 6-fold by ultrafiltration (10 kD cutoff) and the IL-18BP-His₆ was isolated on a Talon column (Clontech) with imidazole as eluant according
5 to the manufacturer's instructions.

Immunological cross-reactivity of the urinary and the COS7-expressed IL-18BP was assessed as follows: Urinary IL-18BP (5 µg) was labeled with ¹²⁵I by the chloramine T procedure. Supernatants of COS7 cells (250 µl) were mixed (1 h, room temperature final volume 500 µl) with the antibody to urinary IL-18BP, diluted 1:1000 in phosphate-buffered
10 saline (PBS), 0.05% Tween 20 and 0.5 % bovine serum albumin (Wash Buffer). ¹²⁵I-labeled urinary IL-18BP (10⁶ cpm) was then added and after 1 h protein G-sepharose (20 µl) was added. The mixture was suspended (1.5 h, 4°C), the beads were then isolated and washed wash 3x Wash Buffer and once in PBS. The beads were then eluted with a Sample buffer, resolved by SDS-PAGE (10% acrylamide under reducing conditions followed by
15 Autoradiography.

IL-18BP_a ran as a single band upon SDS-PAGE with silver staining under reducing and non-reducing conditions and had the same apparent molecular mass as that of the urinary IL-18BP (data not shown). Protein sequence analysis of this preparation revealed the same N-terminal sequence as that of the urinary IL-18BP, indicating that the latter was not
20 degraded at its N-terminus.

Immunoblot analysis of IL-18BP_a with antibodies raised against the urinary IL-18BP revealed the same molecular mass band as that of the urinary protein. Furthermore, using immunoprecipitation followed by SDS-PAGE and autoradiography, IL-18BP_a was able to displace urinary ¹²⁵I-IL-18BP from binding to the antibody. Therefore, IL-18BP_a corresponds
25 structurally to the urinary IL-18BP.

Crude and purified IL-18BP_a was tested for its ability to inhibit the biological activity of IL-18. IL-18BP_a inhibited in a dose dependent manner the IFN-γ inducing activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9).

The results of the various bioassays as well as the mobility shift assay (Example 8) demonstrated that inhibition of IL-18 activity is an intrinsic property of the cloned IL-18BP and not that of any accompanying impurities in urinary IL-18BP, such as the co-eluting fragment of defensin.

5 **Example 8. Electrophoretic mobility shift assays**

The effect of the urinary and the recombinant IL-18BP on IL-18-induced activation of NF- κ B in human KG-1 cells was also studied. Human KG-1 cells (4×10^6 in 1 ml RMPI) were stimulated with either huIL-18 (10 ng/ml) or huIL-18 pre-mixed with an IL-18BP (20 min, room temperature). After 20 min at 37°C, cells were washed three times with ice-cold
10 PBS and immediately frozen in liquid nitrogen. Cell pellets were resuspended in three times the packed cell volume in buffer A (20 mM Tris pH 7.6, 0.4M NaCl, 0.2 mM EDTA, glycerol (20% by volume), 1.5 mM MgCl₂, 2 mM dithiothreitol (DDT), 0.4 mM PMSF, 1 mM Na₃VO₄, 2 μ g/ml each of leupeptin, pepstatin and aprotinin). Cell debris was removed by centrifugation (15,000xg, 15 min.), aliquots of the supernatant were frozen in liquid nitrogen
15 and stored at -80°C. Protein concentration was determined by a Bradford assay (Bio-Rad) using bovine serum albumin as standard. A double-stranded oligonucleotide corresponding to NF- κ B binding element (10 pmol, Promega) was labeled with [³²P]dCTP (300 Ci/mmol) and T4 polynucleotide kinase (New England Biolabs). Free nucleotides were removed by a spin column. Extracts (10 μ g protein) of cells treated with IL-18 or IL-18 plus IL-18BP were
20 incubated (15 min., room temperature) with the labeled probe (3×10^4 cpm) together with poly dI.dC (500 ng, Pharmacia) and denatured salmon sperm DNA (100 ng, Sigma) in 20 μ l buffer consisting of HEPES (pH 7.5, 10 mM), 60 mM KCl, 1 mM MgCl₂, 2 mM EDTA, 1 mM DTT and glycerol (5% by volume). The mixtures were then loaded onto 5% non-denaturing polyacrylamide gels. Electrophoresis was performed at 185 V in 0.5xTBE
25 (40 mM Tris HCl, 45 mM boric acid and 2.5 mM EDTA). Gels were vacuum dried and autoradiographed overnight at -80°C. IL-18 was found to induce the formation of the p50 NF- κ B homodimer and the p65/p50 NF- κ B heterodimer. Urinary as well as recombinant IL-18BP inhibited the activation of NF- κ B by IL-18, as determined by an electrophoretic mobility shift assay with KG-1 cell extracts binding a radiolabeled oligonucleotide
30 corresponding to the NF- κ B consensus sequence.

Example 9. Expression of IL-18BP in E. coli, yeast and insect cells.

IL-18BP may also be produced by other recombinant cells such as prokaryotic cells, e.g., *E. coli*, or other eukaryotic cells, such as yeast and insect cells. Well known methods are available for constructing appropriate vectors, carrying DNA that codes for either IL-18BP and suitable for transforming *E. coli* and yeast cells, or infecting insect cells in order to produce recombinant IL-18BP. For expression in yeast cells, the DNA coding for IL-18BP (Example 6) is cut out and inserted into expression vectors suitable for transfection of yeast cells. For expression in insect cells, a DNA coding for IL-18BP is inserted into baculovirus and the insect cells are infected with said recombinant baculovirus. For expression in *E. coli*, the DNA coding for IL-18BP is subjected to site directed mutagenesis with appropriate oligonucleotides, so that an initiation ATG codon is inserted just prior to the first codon of mature IL-18BP. Alternatively, such DNA can be prepared by PCR with suitable sense and antisense primers. The resulting cDNA constructs are then inserted into appropriately constructed prokaryotic expression vectors by techniques well known in the art (23).

Example 10: Construction of adeno-associated expression vector for in vivo expression of IL-18BP_a

A functional gene coding for IL-18BP_a is constructed based on plasmid pcDNA3 (Invitrogen, San Diego CA). The IL-18BP cDNA with a Kozak consensus sequence at the 5' end is ligated into the Xba I site of pcDNA3 in a way that destroys the restriction site. New Xba I sites are inserted by site-directed mutagenesis before the neomycin cassette (base 2151 of the original pcDNA3 sequence) and after the SV40 polyadenylation signal (base 3372 of the original pcDNA3 sequence). This construct is then cut with Xba I and the resulting 4.7 kb minigen is inserted at the Xba I site of plasmid psub201 as described (Snyder et al, 1996, Current Protocols in Human Genetics, Chapters 12.1.1-12.1.17, John Wiley & Sons). The resulting recombinant plasmid is cotransfected with the helper AAV plasmid pAAV/Ad into human T293 cells. The cultures are then infected with adenovirus as a helper virus and the cells are collected after 48-60 hours of incubation. The cells are subjected to 3 freeze-thaw cycles, cell debris is removed by centrifugation, and the supernatant is brought to 33% saturation with ammonium sulfate. The mixture is then centrifuged and rAAV is precipitated from the supernatant by bringing the ammonium sulfate to 50% saturation. The virus is

further purified by CsCl, dialyzed and finally heated for 15 min at 56°C to destroy any adenovirus.

Example 11: Construction of recombinant fusion proteins of IL-18BP

The production of proteins comprising IL-18BP fused to the constant region of IgG2 heavy chain may be carried out as follows: the DNA of IL-18BP is subjected to site-directed mutagenesis with appropriate oligonucleotides so that a unique restriction site is introduced immediately before and after the coding sequences. A plasmid bearing the constant region of IgG2 heavy chain, *e.g.* pRKCO42Fc1(6) is subjected to similar site-directed mutagenesis to introduce the same unique restriction site as close as possible to Asp 216 of IgG1 heavy chain in a way that allows translation in phase of the fused protein. A dsDNA fragment, consisting of 5' non-translated sequences and encoding for IL-18BP is prepared by digestion at the unique restriction sites or alternatively by PCR with appropriately designed primers. The mutated pRKCD42Fc1 is similarly digested to generate a large fragment containing the plasmid and the IgG1 sequences. The two fragments are then ligated to generate a new plasmid, encoding a polypeptide precursor consisting of IL-18BP and about 227 C-terminal amino acids of IgG1 heavy chain (hinge region and CH2 and CH3 domains). The DNA encoding the fused proteins may be isolated from the plasmid by digestion with appropriate restriction enzymes and then inserted into efficient prokaryotic or eukaryotic expression vectors.

Example 12 : Production of chemically modified IL-18BPs

In order to increase the half-life of the IL-18BPs in plasma, IL-18BPs which are chemically modified with polyethylene glycol (PEG) may be made. The modification may be done by cross linking PEG to a cysteine residue of the IL-18BP molecules. Mutant IL-18BPs may be constructed which contain an extra cysteine residue at the amino terminus, glycosylation sites, and the carboxyl terminus of each IL-18BP. The mutagenesis may be carried out by PCR using oligonucleotides containing the desired mutation. These mutant

proteins are expressed in the usual manner as well known in the art. Pegylation of these proteins will be carried out and the activity will be assessed.

Example 13: Preparation of polyclonal antibodies to IL-18BP

Rabbits were initially injected subcutaneously with 5 µg of a pure preparation of the urinary IL-18BP, emulsified in complete Freund's adjuvant. Three weeks later, they were
5 injected again subcutaneously with 5 µg of the IL-18BP preparation in incomplete Freund's adjuvant. Two additional injections of IL-18BP as solution in PBS were given at 10 day intervals. The rabbits were bled 10 days after the last immunization. The development of antibody level was followed by a radioimmunoassay. ¹²⁵I-labeled IL-18BP (166,000 cpm)
10 was mixed with various dilutions (1:50, 1:500, 1:5,000 and 1:50,000) of the rabbit serum. A suspension of protein-G agarose beads (20 µl, Pharmacia) was added in a total volume of 200 µl. The mixture was left for 1 hour at room temperature, the beads were then washed 3 times and bound radioactivity was counted. Rabbit antiserum to human leptin was used as a negative control. The titer of the IL-18R antiserum was between 1:500 and 1:5000, while
15 that of the negative control was less than 1:50.

EXAMPLE 14: Preparation of monoclonal antibodies to IL-18BP

Female Balb/C mice (3 months old) are first injected with 2 µg purified IL-18BP in an emulsion of complete Freund's adjuvant, and three weeks later, subcutaneously in incomplete Freund's adjuvant. Three additional injections are given at 10 day intervals,
20 subcutaneously in PBS. Final boosts are given intraperitoneally 4 and 3 days before the fusion to the mouse showing the highest binding titer as determined by IRIA (see below). Fusion is performed using NSO/1 myeloma cell line and lymphocytes prepared from both the spleen and lymph nodes of the animal as fusion partners. The fused cells are distributed into microculture plates and the hybridomas are selected in DMEM supplemented with HAT and
25 15% horse serum. Hybridomas that are found to produce antibodies to IL-18BP are subcloned by the limiting dilution method and injected into Balb/C mice that had been primed with pristane for the production of ascites. The isotypes of the antibodies are defined with the use of a commercially available ELISA kit (Amersham, UK).

The screening of hybridomas producing anti-IL-18BP monoclonal antibodies is performed as follows: Hybridoma supernatants are tested for the presence of anti-IL-18BP antibodies by an inverted solid phase radioimmunoassay (IRIA). ELISA plates (Dynatech Laboratories, Alexandria, VA) are coated with Talon-purified IL-18BP_a-His₆ (10 µg/ml, 5 100 µl/well). Following overnight incubation at 4°C, the plates are washed twice with PBS containing BSA (0.5%) and Tween 20 (0.05%) and blocked in washing solution for at least 2 hrs at 37°C. Hybridoma culture supernatants (100 µl/well) are added and the plates are incubated for 4 hrs at 37°C. The plates are washed 3 times and a conjugate of goat-anti-mouse horseradish peroxidase (HRP, Jackson Labs, 1:10,000, 100 µl/well) is added 10 for 2 hrs at room temperature. The plates are washed 4 times and the color is developed by ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, Sigma) with H₂O₂ as a substrate. The plates are read by an automatic ELISA reader. Samples giving OD that are at least 5 times higher than the negative control value are considered positive.

EXAMPLE 15: Affinity chromatography of IL-18BP with monoclonal antibodies

15 Antibodies against IL-18BP are utilized for the purification of IL-18BP by affinity chromatography. Ascitic fluid containing the monoclonal antibody secreted by the hybridoma is purified by ammonium sulfate precipitation at 50% saturation followed by extensive dialysis against PBS. About 10 mg of immunoglobulins are bound to 1 ml Affigel 10 (BioRad USA), as specified by the manufacturer.

20 250 ml of human urinary proteins (equivalent to 250 l of crude urine) are loaded on 0.5 ml of the anti IL-18BP antibody column at 4°C at a flow rate of 0.25 ml/min. The column is washed with PBS until no protein is detected in the washings. IL-18BP is eluted by 25 mM citric acid buffer, pH 2.2 (8 x 1 column volume fractions) and immediately neutralized by 1 M Na₂CO₃. Further purification of this preparation is obtained by size exclusion 25 chromatography.

EXAMPLE 16: ELISA test

Microtiter plates (Dynatech or Maxisorb, by Nunc) are coated with anti-IL-18BP monoclonal antibody (serum free hybridoma supernatant or ascitic fluid immunoglobulins) overnight at 4°C. The plates are washed with PBS containing BSA (0.5%) and Tween 20 (0.05%) and blocked in the same solution for at least 2 hrs at 37°C. The tested samples are diluted in the blocking solution and added to the wells (100 µl/well) for 4 hrs at 37°C. The plates are then washed 3 times with PBS containing Tween 20 (0.05%) followed by the addition of rabbit anti-IL-18BP serum (1:1000, 100 µl/well) for further incubation overnight at 4°C. The plates are washed 3 times and a conjugate of goat-anti-rabbit horseradish peroxidase (HRP, Jackson Labs, 1:10,000, 100 µl/well) was added for 2 hrs at room temperature. The plates were washed 4 times and the color is developed by ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, Sigma) with H₂O₂ as a substrate. The plates are read by an automatic ELISA reader.

EXAMPLE 17 : Non-glycosylated human IL-18BP is biologically active.

Purified recombinant IL-18BP_a was tested for its ability to inhibit the biological activity of IL-18. IL-18BP_a inhibited in a dose dependent manner the IFN-γ inducing activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9).

Purified IL-18BP_a having an His₆ tag at the C-terminus (1.5 µg, 50 µl) was adjusted to pH 7.5 and mixed with N-glycosidase F (3 µl, 500,000 U/ml, PNGase F, New England Biolabs). The mixture was incubated for 24 h at 37°C under non-denaturing conditions. Aliquots from the sample and from undigested IL-18BP-His₆ were analyzed by SDS-PAGE under non-reducing conditions followed by immunoblotting with antibodies to IL-18PB. It was found that the ~40 kD band of IL-18BP-His₆ disappeared in the PNGase-treated fraction and a new ~20 kD band was obtained. The molecular mass of the product and the specificity of PNGase F indicated that IL-18BP-His₆ was fully deglycosylated.

The PNGase-treated fraction, undigested IL-18BP-His₆ and control sample containing PNGase in buffer were absorbed separately on Talon beads, washed with phosphate buffer and eluted with imidazole (100 mM). The eluted fractions were subjected to bioassay using human IL-18 (20 ng/ml), LPS (2 µg/ml) and murine splenocytes. The

5 results are shown in the following table:

Sample	IFN- γ (ng/ml)
Control	7.5
Non-digested IL-18BP-His ₆	0
PNGase-treated IL-18BP-His ₆	0

Therefore, it is concluded that deglycosylated IL-18BP is biologically active as a modulator of IL-18 activity.

10 The foregoing description of the specific embodiments reveal the general nature of the invention so that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of
15 description and not of limitation.

References

1. **Anderson, D.M., et al.,** *A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.* *Nature*, 1997. **390**(6656): p. 175-179.
2. **Bollon, D. P., et al.** (1980) *J. Clin. Hematol. Oncol.* **10**:39-48.
- 5 3. **Botstein, D., et al.** (1982) *Miami Wint. Symp.* 19:265-274.
4. **Broach, J. R.,** in "The Molecular Biology of the Yeast *Saccharomyces*: Life Cycle and Inheritance", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 445-470 (1981).
5. **Broach, J. R.,** (1982) *Cell* **28**:203-204.
- 10 6. **Byrn R. A. et al.,** 1990, *Nature* (London) **344**:667-670.
7. **Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel.** 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock. *J. Exp. Med.* **179**:1437-44 issn: 0022-1007.
8. **Chater, K. F. et al.,** in "Sixth International Symposium on Actinomycetales
15 *Biology*", Akademiai Kiado, Budapest, Hungary (1986), pp. 45-54).
9. **Conti, B., J. W. Jahng, C. Tinti, J. H. Son, and T. H. Joh.** 1997. Induction of interferon-gamma inducing factor in the adrenal cortex. *J. Biol. Chem.* **272**:2035-2037.
10. **Dao, T., K. Ohashi, T. Kayano, M. Kurimoto, and H. Okamura.** 1996. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated
20 cytotoxicity of murine T helper 1 cells. *Cell-Immunol.* **173**:230-5 issn: 0008-8749.
11. **Engelmann, H., D. Aderka, M. Rubinstein, D. Rotman, and D. Wallach.** 1989. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. *J. Biol. Chem.* **264**:11974-11980.

12. Engelmann, H., D. Novick, and D. Wallach. 1990. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. *J. Biol. Chem.* **265**:1531-1536.
- 5 13. Fantuzzi, G., et al., *IL-18 regulation of IFN-g production and cell proliferation as revealed in interleukin-1b converting enzyme-deficient mice.* *Blood*, 1998. **91**: p. 2118-2125.
14. Gryczan, T., "The Molecular Biology of the Bacilli", Academic Press, NY (1982), pp. 307-329).
- 10 15. Gutkind, J.S., et al., *A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes but not in normal monocytes.* *Molec. Cell. Biol.*, 1991. **11**: p. 1500-1507.
16. Heremans, H., J. Van Damme, C. Dillen, R. Dijkmans, and A. Billiau. 1990. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. *J. Exp. Med.* **171**:1853-69 issn: 0022-1007.
- 15 17. Izaki, K. (1978) *Jpn. J. Bacteriol.* **33**:729-742).
18. John, J. F., et al. (1986) *Rev. Infect. Dis.* **8**:693-704).
19. Kendall, K. J. et al. (1987) *J. Bacteriol.* **169**:4177-4183).
20. Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto. 1997. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. *J. Immunol.* **158**:1541-1550.
- 20 21. Maliszewski, C. R., T. A. Sato, T. Vanden Bos, S. Waugh, S. K. Dower, J. Slack, M. P. Beckmann, and K. H. Grabstein. 1990. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. *J. Immunol.* **144**:3028-3033.
- 25

22. Maniatis, T., in "Cell Biology: A Comprehensive Treatise, Vol. 3: Gene Expression", Academic Press, NY, pp. 563-608 (1980).
23. Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1982.
- 5 24. Micallef, M. J., T. Ohtsuki, K. Kohno, F. Tanabe, S. Ushio, M. Namba, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, S. Fukuda, and M. Kurimoto. 1996. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. *Eur-J-Immunol* 26:1647-51 issn: 0014-2980.
- 10 25. Mizushima, S. and Nagata, S. (1990) pEF-BOS, a powerful mammalian expression vector. *Nucleic Acid Res.* 18:5322-5328.
26. Nakamura, K., H. Okamura, K. Nagata, T. Komatsu, and T. Tamura. 1993. Purification of a factor which provides a costimulatory signal for gamma interferon production. *Infect-Immun* 61:64-70 issn: 0019-9567.
- 15 27. Nakamura, K., H. Okamura, M. Wada, K. Nagata, and T. Tamura. 1989. Endotoxin-induced serum factor that stimulates gamma interferon production. *Infect-Immun* 57:590-5 issn: 0019-9567.
28. Novick, D., B. Cohen, and M. Rubinstein. 1994. The Human Interferon alpha/beta
20 Receptor - Characterization and Molecular Cloning. *Cell* 77:391-400.
29. Novick, D., B. Cohen, and M. Rubinstein. 1992. Soluble Interferon-alpha Receptor Molecules Are Present in Body Fluids. *FEBS Lett* 314:445-448.
30. Novick, D., H. Engelmann, D. Wallach, and M. Rubinstein. 1989. Soluble cytokine receptors are present in normal human urine. *J. Exp. Med.* 170:1409-1414.
- 25 31. Okamura, H., H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, K. Akita, M. Namba, F. Tanabe, K. Konishi,

- S. Fukuda, and M. Kurimoto. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. *Nature* 378:88-91.
32. Rothe, H., N. A. Jenkins, N. G. Copeland, and H. Kolb. 1997. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is
5 located near Idd2. *J-Clin-Invest* 99:469-74 issn: 0021-9738.
33. Sambrook, J., E.F. Fritsch, and M. T., *Molecular Cloning: A laboratory manual*. 2nd ed. ed. 1989, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.
34. Simonet, W.S., et al., *Osteoprotegerin: a novel secreted protein involved in the regulation of bone density*. *Cell*, 1997. 89(2): p. 309-319.
- 10 35. Sompayrac, L.H. and K.L. Danna, *Efficient infection of monkey cells with DNA of simian virus 40*. *Proc. Nat'l. Acad. Sci. USA*, 1981. 78: p. 7575-7578.
36. Sparks, C.A., et al., *Assignment of the nuclear mitotic apparatus protein NuMA gene to human chromosome 11q13*. *Genomics*, 1993. 17: p. 222-224.
37. Tsutsui, H., K. Nakanishi, K. Matsui, K. Higashino, H. Okamura, Y. Miyazawa,
15 and K. Kaneda. 1996. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. *J. Immunol.* 157:3967-73 issn: 0022-1767.
38. Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, K. Torigoe, T. Tanimoto, S. Fukuda, M. Ikeda, H.
20 Okamura, and M. Kurimoto. 1996. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in *Escherichia coli*, and studies on the biologic activities of the protein. *J. Immunol.* 156:4274-4279.34. Okayama, H. and Berg, P. (1983) A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. *Mol. Cell. Biol.* 3:280-289.
39. Yasuda, H., et al., *Identity of osteoclastogenesis inhibitory factor (OCIF) and
25 osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro*. *Endocrinology*, 1998. 139: p. 1329-1337.

SEQUENCE LISTING

<110> Novick, Daniela
 Dinarello, Charles
 Rubinstein, Menachem
 Kim, Soo Hyun
 Yeda Research and Development Co. Ltd.

<120> Interleukin-18 Binding Proteins, their Preparation and Use

<130> IL-18 Rubinstein

<140>
 <141>

<150> 125463
 <151> 1998-07-22

<150> 122154
 <151> 1997-11-06

<150> 121869
 <151> 1997-09-29

<150> 121639
 <151> 1997-08-27

<150> 121554
 <151> 1997-08-14

<160> 10

<170> PatentIn Ver. 2.0

<210> 1
 <211> 1348
 <212> DNA
 <213> Homo sapiens

<400> 1
 gagaagagga cgttgtcaca gataaagagc caggctcacc agctcctgac gcatgcatca 60
 tgaccatgag acacaactgg acaccagacc tcagcccttt gtgggtcctg ctctgtgtg 120
 cccacgtcgt cactctcctg gtcagagcca cacctgtctc gcagaccacc acagctgcca 180
 ctgctcagt tagaagcaca aaggaccctt gccctccca gcccccagtg ttcccagcag 240
 ctaagcagt tccagcattg gaagtgaact ggccagaggt ggaagtgcca ctgaatggaa 300
 cgctgagctt atcctgtgtg gctgcagcc gcttcccaa cttcagcacc ctctactggc 360
 tgggcaatgg ttccttcatt gagcacctcc caggccgact gtgggagggg agcaccagcc 420

```

gggaacgtgg gagcacaggt acgcagctgt gcaaggcctt ggtgctggag cagctgaccc 480
ctgccctgca cagcaccacac ttctcctgtg tgctcgtgga ccctgaacag gttgtccagc 540
gtcacgtcgt cctggcccag ctctgggctg ggctgagggc aaccttgccc cccacccaag 600
aagccctgcc ctccagccac agcagtcac agcagcaggg ttaagactca gcacagggcc 660
agcagcagca caaccttgac cagagcttgg gtcctaactg tctacctgga gtgaacagtc 720
cctgactgcc tgtaggctgc gtggatgcgc aacacacccc ctctctctct gctttgggtc 780
ccttctctca ccaaatcaaa actccattcc cacctaccta gaaaatcaca gccctcctat 840
aatgcctcct cctcctgcca ttctctctcc acctatccat tagccttctt aacgtcctac 900
tcccacact gctctactgc tcagaaacca ccaagactgt tgatgcctta gccttgcact 960
ccagggcctt acctgcattt cccacatgac tttctggaag cctcccacac attcttgctt 1020
ttcccagaca gctcccactc ccatgtctct gctcatttag tcccgtcttc ctccaccgcc 1080
cagcagggga acgctcaagc ctggttgaaa tgctgcctct tcagtgaagt catctcttt 1140
cagctctggc cgtattctgc agacttctta tctcgtgct gtatgttttt tttttccccc 1200
ttcactctaa tggactgttc cagggaaagg atgggggcac cagctgcttc ggatccacac 1260
tgtatctgtg tcatccccc acatggctctc ataaaggatt attcaatgga aaaaaaaaaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1348
    
```

<210> 2
 <211> 192
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)..(28)

<400> 2
 Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
 1 5 10 15
 Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
 20 25 30
 Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
 35 40 45
 Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
 50 55 60
 Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly Thr Leu
 65 70 75 80
 Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser Ile Leu
 85 90 95
 Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly Arg Leu
 100 105 110

Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr Gln Leu
 115 120 125

Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His Ser Thr
 130 135 140

Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln Arg His
 145 150 155 160

Val Val Leu Ala Gln Leu Trp Ala Gly Leu Arg Ala Thr Leu Pro Pro
 165 170 175

Thr Gln Glu Ala Leu Pro Ser Ser His Ser Ser Pro Gln Gln Gln Gly
 180 185 190

<210> 3
 <211> 1038
 <212> DNA
 <213> Homo sapiens

<400> 3
 gagaagagga cgttgtcaca gataaagagc caggctcacc agctoctgac gcattgcata 60
 tgaccatgag acacaactgg acaccagacc tcagcccttt gtgggtctcg ctccctgttg 120
 cccacgtcgt cactctcctg gtcagagcca cacctgtctc gcagaccacc acagctgcc 180
 ctgctcagc tagaagcaca aaggaccct gccctccca gcccacagtg ttcccagcag 240
 ctaagcagtg tccagcattg gaagtaccc gccagaggt ggaagtcca ctgagctggg 300
 ctgagggcaa ccttgcctcc caccacaaga gccctgccct ccagccacag cagtccacag 360
 cagcaggggt aagactcagc acagggccag cagcagcaca accttgacca gagcttgggt 420
 cctacctgac taccctggag gaacagctcc tgactgcctg taggctgctg ggatgcgcaa 480
 cacaccctct ccttctctgc tttgggtccc ttctctcacc aaattcaaac tccattccca 540
 cctaccctaga aaatcacagc ctcttataa tgctctctcc tcttgcctat ctctctccac 600
 ctatccatta gccttccata cgtctctacc ctccactgc tctactgctc agaaaccacc 660
 aagactgttg atgccttagc cttgcactcc agggccctac ctgcatttcc cacatgactt 720
 tctggaagcc tcccaactat tcttgccttt cccagacagc tcccactccc atgtctctgc 780
 tcatttagtc ccgtcttctt caccgcccca gcaggggaac gctcaagcct ggttgaaatg 840
 ctgctctctc agtgaagtc tctctcttca gctctggcag cactctgcag acttctctac 900
 ttctgtctgt atgttttttt tttccccctt cactctaatg gactgttcca gggaaagggat 960
 gggggcacca gctgcttcgg atccacactg tatctgtgac atccccacat gggctctcat 1020
 aaaggattat tcaatgga 1038

<210> 4
 <211> 113
 <212> FRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)..(28)

<400> 4
 Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
 1 5 10 15
 Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
 20 25 30
 Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
 35 40 45
 Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
 50 55 60
 Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Ser Trp Ala Glu
 65 70 75 80
 Gly Asn Leu Ala Pro His Pro Arg Ser Pro Ala Leu Gln Pro Gln Gln
 85 90 95
 Ser Thr Ala Ala Gly Leu Arg Leu Ser Thr Gly Pro Ala Ala Ala Gln
 100 105 110
 Pro

<210> 5
 <211> 7063
 <212> DNA
 <213> Homo sapiens

<400> 5
 gaattcgcgg ccgcgtcgac gccagagggg ctaggatgag agacagaggg tctgatggtg 60
 ggtgctggga aatgtaccoc accttggggc tggtagctgg gggagtgggt agcctgggaa 120
 aggccaggat gtggacggac tggtaggca ttgagcctga agtgggtccaa cttggggttc 180
 cccagtgccr aggaagttg tccccttgaa tgtcagtgtg aaggtgaagg aggaagcaga 240
 tgccctgttca tatggaaaca aagacctggc tgtgaagagg ggagggcggac accaaagtcc 300
 tgacacttgg gcgggacaga attgatctgt gagagactca tctagtccat accctaggtg 360
 accctggggg tggcatgggg gtagattaga gatcccagtc tggtagcttc tggagagtag 420
 gagtcccagg agctgaaggt ttctggccac tgaactttgg ctaaagcaga ggtgtcacag 480
 ctgctcaaga ttccctgggt aaaaagtga aagtgaatag agggtcgggg cagtgtcttc 540
 ccagaaggat tgctcggcat cctgccttc ccagaagcag ctctggtgct gaagagagca 600
 ctgcctccct gtgtgactgg gtgagtccat attctctctt tgggtctcaa ttttgcttc 660

cctaataagagg gggtaagatt ggactaggtta agcatcttac aaccatttgt ggtcatgaga 720
 gctgggggtgg ggaaggattg tcacttgacc cccccagctc tgtttctaag tgctgaaaga 780
 gctccaggct atgctacggg aggagaagcc agctactgag gaaaagccag ctaactgaga 840
 aaagcggggag tggttacca ttctctccc scacccttca ccagagaaga ggacgttgc 900
 acacataaag agccaggctc accagctctc gacgcatgca tcatgacat gagacacaac 960
 tggacaccag acctcagccc ttgtgtggct ctgctcctgt gtgccacgt cgtcactctc 1020
 ctggtcagag ccacacctgt ctgcagacc accacagctg ccaactgcctc agttagaagc 1080
 acaaaaggacc cctgcccctc ccagcccaca gtgttcccag cagctaagca gtgtccagca 1140
 ctggaagtga cctggccaga ggtggaagt ccactgaatg gaacgctgag ctatcccgt 1200
 gtggcctgca gccgttccc caacttcagc atcctctact ggctgggcaa tggttccctc 1260
 attgagcacc tcccaggccg actgtgggag gggagcaca gccgggaacg tgggagcaca 1320
 ggtacgcagc tgtgcaaggc ctgtgtgctg gacgagctga ccctgccct gcacagcacc 1380
 aactctccc gtgtgctcgt ggaccctgaa cagggtgtcc agcgtcacgt cgtcctggcc 1440
 cagctcctgg tgaaggacc aaggagaggc ctccaggaac aggaggagct ctgctccat 1500
 atgcggggag gaaagggtg gctctgccag agcagcctgt gaactaatgc ccagcctcc 1560
 tcaaggctcag ccagacaaaa aggaacttag gtcttgggca gaggagggtg agcctggggc 1620
 aaagtgatga gatgtctctc ctctctctgg cctgatoctt gtctgccttc acttccctag 1680
 gctgggctga gggcaacct gcccccacc caagaagccc tgcctccag ccacagcagt 1740
 ccacagcagc agggtaaga ctccagcagc ggcagcagc agcacaacct tgaccagagc 1800
 ttgggtccta cctgtctacc tggagtgacc agtccctgac tgcctgtagg ctgcgctgat 1860
 gcgcaacaca cccctcctc ctctgcttgg ggtccctct ctccacaaat tcaaacctca 1920
 ttcccacctc cctagaaaa cccagcctcc ttataatgcc tctcctcct gccattctct 1980
 ctccacctat ccattagcct tccaaagct ctaactctca cactgctcta ctgctcagaa 2040
 accaccaaga ctgttgatgc cttagccttg cactccaggg ccctacctgc atttcccaca 2100
 tgacttctg gaagcctccc aactattctt gcttttccca gacagctccc actcccatgt 2160
 ctctgctcat ttagtccctt ctctctcacc gcccagcag gggaacgctc aagcctgggt 2220
 gaaatgctgc ctctcagtg aagtcactct ctctcagctc tggccgcatt ctgcagact 2280
 cctactctcg tgcgtatgt ttttttttc cccctcact ctaatggact gttccagga 2340
 agggatgggg gcagcagctc ctctcgatcc aactgtatc tgtgtcatcc ccacatgggt 2400
 cctcataaag gattattcaa tggaggcacc ctgacatctg ttcatatagg ctccagctcc 2460
 actcccagga actttgcctg tcccacgagg gagtatggga gagatggact gccacacaga 2520
 agctgaaagc aacacctgct tcaggggaa acagggcgtt gaaaaagaaa agagagaaca 2580
 gccctactag ctcccggga gcagagggca ctaatggaga gtgggaagag cctggaaaqa 2640
 tgtggcctca ggaagggga tgagagaaa gagggtggtat ggaagactca gcaggaaca 2700
 ggtaggcttc aaagagccta tattctctt tttcccacac cgatcaagtc aactcagctc 2760
 tcacgggaga aaaatagact ttatttaca gtaataacat ttgaaaaaga tccatccccg 2820
 gccctaaaa accttcccat cactccaaat cccaccaccag tcaagctctg gggagggtag 2880
 ggtgtgagct gctgctgag gctgtcccc aaccocactc ctgagacaca gggcccctcc 2940
 gtctgggaa agagcatcct ctggcaggtg ctcccaccag gtcagaccca gtcctggact 3000
 tcaagagtg gggccctgc tgggcccagc caccagga caaggaacca gggcctactc 3060
 ctcttatggt ccttctaga tccagaggct aagaggaaga ctggccaggg ccaaggaccc 3120
 agccatcaaa accagcctca aatctggtt tgatggagaa gtgactttgc ttaagaaaa 3180
 aaggaggcaa ggtagggaga gcgccacac tgtccatgct ccaggccccc tgggccagct 3240
 ccgagaaggc gccagtgag gaccagggac caggccaggg tgcgggcagg catcactgct 3300
 tctagggtt tggctactgt tggcctggga gctgagagaa ggcactgaga gggacagtag 3360
 gcggaggacc aggtgacggc agcatcggg acacaggtgg ggcactcacc tggtagctgc 3420
 cctttagtgc tttgctgaa agagacacag tcaatggcc agatgagaac ttgcgact 3480
 agcctgacc cactggctgg gaagatctt tctgctccc acgcccctgt ctggatcccc 3540

tcccttgtga gccccagggt tatcagttgc tggctgtgoc tgagcagctc tgggtgctct 3600
 ccatgagaat ggggccatct gtcttctctc cttggagagg agctaccagg acagggacac 3660
 ctcttaccce acaccctcca gcagcctggc grggcccat cttggatgct acttgggtggg 3720
 ggggtctggg ggggtgccat gctctcatcg ggtttccctc ccccatcctg ccagtgcctc 3780
 taccttgccc ttggctcgag ggggtggcacc aatggcggca gcagtggcgg cgctggctgt 3840
 ggtggtggca atgocggag aacggcgggt tccactgcga gtgttggggg aagccttggg 3900
 cagggccttc tttgaggtc cccgccgag aaggctgttc cctagcttct tgggtgtgtt 3960
 gaggatgctg aaggccatcg actggcggc gtcagcctgc aaggaagggc tgtcagaccg 4020
 ggagacccaa tctgctcttc ccaggccagc gtgctgtgoc acgctgtacc agcaaggctc 4080
 cgccagggcg tgccttcac cccctcagc cccagcctca cctgtttagt agaagctgga 4140
 gctgctttct tctgggcctc agtagtgcct tgtttgcgcc ctctatgtcg gtctcgggga 4200
 gtcattggggc gtgggaaaca gctggtggcc ttcttagact atggagaaga ggacagttag 4260
 gcagacagta gcaagaggag tcacatctga agccaggtgt cttgtcctct cagagctgag 4320
 tggaccctgt aagtcacagt gcaacctgct ccccttccca actctgggcc agatccttcc 4380
 cttcccaaca gttcccatcc atgggtcagg cccctggaga gagggaaaga gagggggaag 4440
 tgaggggaag agagagaagg ctcccttag tcttgggtga gctgggcctg acctgagcac 4500
 agtctggag taacaccag gagccaccgc gcctacctca ggagtccag ggccctgggtg 4560
 gggctctagg gagaccgct tgcgctgctg ccgggtgggt atgccagtc cctcggctat 4620
 ctggattggc tgcattgctg ctggcgag ggctctcttg ggtctccaag tttctatctc 4680
 ctcatctgtg atggtgcca ggtcagggg aggtgctatg ggtggaagag gtggtcagtg 4740
 gaccatagct gtagggagat ggagggagc ctgggctgt tccagaactc tacactcgcc 4800
 cgacacctat ggtcgggacc ctctctgctc acgaggtaga aagacacaag cctccttcc 4860
 tgttctgctt tctacctaa cctcgggcaa atggcacaag cagtgcagtc ctgaccagat 4920
 tectctctga gctcctgct acccccagg acttcacccc tgagtgcct ccagctgtct 4980
 gttccacctg gaacatgaga aggtcaccoc ttccctctt cggccagtcg gtgatccagg 5040
 gccctagtgc tccaggctaga tccagcagtg gatttccaa gaaggccagg gatgggaggc 5100
 cctgcacagt gaccccaggc ctccacctgg actccagggg tagcaggtct tccagatgtg 5160
 ggggcacact cgtatgctc gctgcagctc tgcaatgctg ttccagtcac ccagctgctc 5220
 aggtctatcc tggcaagtgc ccatgtagaa gctgttctct cctgtggaag gcagggaagt 5280
 gggaaacaat gagcctggag tggcaggtc acctcctggc cctggcatct tggcagcctt 5340
 tgcggccacc taaccataa acttgaagcc cggcacacca gtctgattca gtgcccagg 5400
 tgcaggagta cggcacacag actatttcta tccatggggc ttgctcacca ccttctcct 5460
 ggagagggca gaagaggctc cacgcagaga ctgctactac atcttattca cctgccaagg 5520
 cttggtggcc aacaccaga ggaacaaatt aaggaccggg aattaattcc caggggctcc 5580
 ctggtgcccc aaggacaaga gcttccaaga agagtctggc cagcctggcc tttccagcag 5640
 cccatcaccg cctgagaagg gcatggagg ctccccacag ctaagtgtca caattgtgct 5700
 gggaaatccc ggccttaac tctggttaag agtgcctcca acacagccag cccctagatg 5760
 ggcaggtaaq gaaggccctg aggtgcagag aaggaggggc aggtggagct ggtggtagc 5820
 aaggaggcca gcttggatt tttaaaaagc tttcctcttt tccctgtgcc acgatccacc 5880
 ttccagtcta attttgggt atagtaagtc cctgtagctc cctcactgg aggggcccc 5940
 ctggacaccc cggcctggga acgacgagca gaactgcgag tgggtggggc gtaccaggc 6000
 aagctgagca gggctgagtt gccataatcg ggagaaccca ggcgagctag agactgagta 6060
 gaggaggtgg ctgcagggct agcctgggaa gcaggagcag accgctgct gtagaacgat 6120
 gagtggcgc tctctggctc ttccacatct agcttctgga agacagagtg aatctgttgc 6180
 agtgtacagt cctggcact gtacagaagc ttccattcc cttccgaagc cctcagatcc 6240
 cacggcacat ccatgtattc ccaactgctt tgcaaggctc cttaaagtgt gtgtctgca 6300
 gaaatgggcc tctgcagag aagcctcac aagggtgtgc tgatgtgtc aagactctc 6360
 tacgcatttt tctcatggag tctattcata atgctttgag gtagggaatg cagagtgttt 6420

atcggcccat ttggagatg aagtgcaaag aaataaagt actagcccca aatcacactg 6480
 cttaggaagta tcagagctgg ggctaggccc catgtctcct gactagtcat gctcatcccc 6540
 cagcctctgc tgccctcag tccaaacttc cagggccctt accatgttcc agaacttccc 6600
 ccaacttctt ggtagcaggg ggcaccctaa acacacaggt cccccctgct gtaccagggg 6660
 cccccctccc cctcctccc aacctcccct tcaagatgtg gaaacaaagg caagggcctg 6720
 cagcctgtca ggcagtccac tgggcagcaa caatgcctct cagctgcatg gggcatgctg 6780
 ggaggcacag gatgggctgc agcttcgcca cgttctctcc cttcacctcg cacaggctca 6840
 gtgctacgca tggagagaat gctagcctta gtcaggaggc agggatctaa tcttagccct 6900
 gcccttttct tcagaagtgc ccttaaccaa gtcactgccc tttttaagac ctctcagctt 6960
 tcccactgta acatggactg gctgctcacc cctccctgct cctgactgag tgcccagtgc 7020
 aaagatgccc ttgagaggaa gtgggaattg ctgacctgac gac 7063

<210> 6
 <211> 197
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SIGNAL
 <222> (1)..(28)

<400> 6
 Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
 1 5 10 15
 Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
 20 25 30
 Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
 35 40 45
 Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
 50 55 60
 Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly Thr Leu
 65 70 75 80
 Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser Ile Leu
 85 90 95
 Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly Arg Leu
 100 105 110
 Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr Gln Leu
 115 120 125
 Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His Ser Thr
 130 135 140

<220>

<221> SIGNAL

<222> (1)..(28)

<400> 8

```

Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
  1           5           10           15

Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
           20           25           30

Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
           35           40           45

Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
           50           55           60

Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly Thr Leu
           65           70           75           80

Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser Ile Leu
           85           90           95

Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly Arg Leu
           100           105           110

Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Trp Ala Glu
           115           120           125

Gly Asn Leu Ala Pro His Pro Arg Ser Pro Ala Leu Gln Pro Gln Gln
           130           135           140

Ser Thr Ala Ala Gly Leu Arg Leu Ser Thr Gly Pro Ala Ala Ala Gln
           145           150           155           160

Pro
    
```

<210> 9

<211> 7812

<212> DNA

<213> Homo sapiens

<400> 9

```

gtcgcacggta cccccgggaa agatttaata cgactcacta tagggcggga cagaattgat 60
ctgtgagaga ctcactagt tcatacccta ggtgaccctg ggggtggcat ggggtagat 120
    
```

tagagatccc agtcttggtat cctctggaga gtaggagtc caggagctga aggtttctgg 180
 ccaactgaact ttggctaaaag cagaggtgtc acagctgctc aagattccct ggtaaaaaag 240
 tgaagtga atagagggtc ggggcagtgc tttcccagaa ggattgctcg gcattcctgcc 300
 cttcccagaa gcagctctgg tgctgaagag agcactgcct cctgtgtga ctgggtgagt 360
 ccataattctc tctttgggtc tcaattttgc cttccctaat gaagggttaa gattggacta 420
 ggtaagcacc ttacaacccat ttgtggtcat gagagctggg gtggggaagg attgtcactt 480
 gaccccccca gctctgtttc taagtgtcta aagagctcca ggctatgcta cgggaggaga 540
 agccagctac tgagaaaaag ccagctactg agaaaaagcg ggagtgggtt accattctcc 600
 tccccacact tcaccagag aagaggactg tgtcacacat aaagagccag gctcaccagc 660
 tctctgacga tgcctcatga ccatgagaca caactggaca ccaggtaggc cttggggcta 720
 cgcattggca ggcgggtgag ggtgaggtct atgaaccagaa tggagcaatg ggtaaccgg 780
 gagccttcac tccaaggcaa accaccagc gcacctgggt ctgtgtctt aagaacctgg 840
 gcagatatg tagctctggc tccagctaa agcttctctg tactctgtc aataaagggc 900
 taagggtggt gtgctgagg gtccctcttc ccgctctgat tccctggcta gaaccagac 960
 atctctgggc tggagttaca tctctaccgc ggcagccac tctgtctca gagccgctga 1020
 cctgtaactg tctttctc agacctcagc cctttgtggg tctctgctct gtgtgccac 1080
 gtcgtcactc tctgtctcag agccacacct gtctgcaga ccaccacagc tgccactgcc 1140
 tcagttagaa gcacaaagga cccctgcccc tcccagcccc cagtgtccc agcagctaag 1200
 cagtgtccag cattggaagt gacctggcaa gaggtggaag tcccactgag taagaagcac 1260
 agtgggtggag ggtgggtctat gggcacagag gttcccaggg tgggttgac tctgagcgc 1320
 cagtccccct ctgccatgt accaccagct gagccagctg ggctgagcac gcaccattct 1380
 cctccccaa cccagtgta tgggtgcagg cttgggcag cccccaaagat gctccctatc 1440
 aatataggaca gagaactcaa gacataagta atggtcacag gacctcccag agccttggtt 1500
 gcagtggacc ccaaggccag cccctccacc cagagcctgc tggcctctgg ccatctcaga 1560
 ggagcagcag ccattccagca ctgctctctg cacctgggct cccaaagtcac cgggctggg 1620
 cactagaaaa ggtcattcctg agggagacagg ttcagaagag gattcatcac gtgaaccaag 1680
 gaccattcct cacattcccc gtgtttaggg ctagggcctc tgggagacaa ctgcaactct 1740
 gtaacggacg tccccacta ggtggtgtgc agagcagttc tctaggttcc agatgcatgg 1800
 ggactggggg gactgtgcag agagggcaca gcagagcagg gtaggggaag ggctgtctt 1860
 tctgaagagc taactgctgc ctgtgtccct agatggaacg ctgagcttat cctgtgtggc 1920
 ctgcagccgc tccccaaact tcagcattct ctactggctg gccaatgggt ccttcattga 1980
 gcaectccca ggcgactgt gggaggggag caccaggtga ggtcgcagc agccaggtgg 2040
 gtgggaagga agcctctctg ggccttctca tgaccttcc tccccctccg ctccagccgg 2100
 gaacgtggga gcacaggtac gcagctgtgc aaggccttgg tgcaggagca gctgaccctt 2160
 gcectgcaca gcaccaactt ctctgtgtg ctctgtggacc ctgaacaggt tgtccagcgt 2220
 cacgtctctc tggcccagct ctgggtgagg agcccaagga gaggcctcca ggaacaggag 2280
 gagctctgct tccatatgtg gggaggaaa ggtgggtctt gccagagcag cctgtgaact 2340
 aatgcccagc attcctcaag gtcagccaga caaaaaggaa cttaggtctt gggcagagga 2400
 ggtgtagcct ggggcaaaag gatgagatgt cctccttct cttggcctga tcttctctg 2460
 cctcacttct cctaggtctg gctgagggca accttgcctc ccaccaaga agcctctgcc 2520
 tccagccaca gcagtccaca gcagcagggt taagactcag cacagggcca gcagcagcag 2580
 aaccttgacc agagcttggg tctacctgt ctacctggag tgaacagctc ctgactgctt 2640
 gtaggctgct tggatgcgca acacaccccc tcttctctg ctttgggtcc cttctctcac 2700
 caaattcaaa ctccattccc acctacctag aaaaacacag cctccttata atgctcctc 2760
 ctctgacct tctctctcca cctatccatt agccttctca acgtcctact cctcactg 2820
 ctctactgct cagaaaaccac caagactgtt gatgccttag ccttgcactc cagggcctta 2880
 cctgcattc ccacatgact ttctggaagc ctcccaacta ttctgtctt tccagacag 2940
 ctccccactc catgtctctg ctcathtagt cccgtcttcc tcaccgcccc agcaggggaa 3000

cgctcaagcc tggttgaat gctgectctt cagtgaagtc atcctctttc agctctggcc 3060
 gcattctgca gacttccctat cttcgtgctg tatgtttttt ttttccccct tcaacttaat 3120
 ggactgttcc agggaagggg tgggggcagc agctgcttcg gatccacact gtatctgtgt 3180
 carccccaca tgggtccctca taaaggatta ttcaatggag gcatcctgac atctgttcat 3240
 ttaggcttca gttccactcc caggaacttt gctgtcccca cgagggagta tgggagagat 3300
 ggactgccac acagaagctg aagacaacac ctgcttcagg ggaacacagg cgcttgaaaa 3360
 agaaaagaga gaacagccca taatgctccc cgggagcaga ggccactaat ggagagtggg 3420
 aagagcctgg aaagatgtgg cctcaggaaa agggatgaga gaaaggaggt ggtatggaag 3480
 actcagcagg aacaaggtag gcttcaaaag gcctatatc ccttttttcc cacaccgata 3540
 aagtcaactc agtactcacg ggagaaaaat agactttatt tacaagtaat aacattttaga 3600
 aaagatccat ccccgccctt taaaaacctt cccatcactc caaatcccc cccagtgcac 3660
 gtctggggaa ggtagggtgt gaqctgctgc tgaaggctgt cccccaaccc cactcctgag 3720
 acacagggcc catccgtcct gggaaagagc atcctctggc aggtgctccc accaggtcag 3780
 acccagtcct ggacttcaag agtgagggcc cctgctgggc ccagccacca ggacagcagg 3840
 aaccagggcc tactcctctt atggtccctt ctagatccag aggctaagag gaagactggc 3900
 caggcccaag gacccagcca tcaaaaccag cctcaaatct ggtgtgatg gagaagtgac 3960
 ttgtctttaa gaaaaaagga ggcaaggtag ggagagcggc cacactgtcc atgctccagg 4020
 cccccgggc cagctccgag aaggccgccc tgaaggacca gggaccaggc caggtgctgg 4080
 gcaggcatca ctgtctctag gggcttggct actgttggcc tgggagctga gagaaggcac 4140
 tgagagggac agtagggcga ggaccaggtg acggcagcat cggggacaca ggtggggcca 4200
 ctcaactgta ctggcccttt agtgccttgc ctgaaagaga cacagtcaca tggccagatg 4260
 agaacttgcg ataactagcct gcaccactg gctgggaaga tctctctctg ctcccacgcc 4320
 cctgtctgga tccccctcct tgtgagcccc agggttatca gttgctggct gtgctgagc 4380
 agctctgggt gctctccatg agaatggggc catctgtctt ctctccttgg agaggagcta 4440
 ccaggacagg gacacctctt accccacacc ctccagcagc ctggcgtggc cccatcttgg 4500
 atgctaactg gtggggcggg ctgggggggt cccatgctct catcgggttt cctccccca 4560
 tctgcccagt gccctctacc tgccttggc tgcaggggtg gcaccaatgg cggcagcag 4620
 ggcggcgtg gctgtggtg tggcaatgc cggagaacgg cgggttccac tgcgagtgtt 4680
 gggggaagcc ttggacaggg ccttcttga ggtccccgc cgcagaaggc tgttccctag 4740
 ctctctgggt gtgttgagga tgcgtaaggc catcgactgg cgcgggtcag cctgcaagga 4800
 agggctgtca gaccgggaga cccaatgctg ccttcccagg ccagcgtgct gtgccacgct 4860
 gtaccagcaa ggtccccca gggcgtcgt tcatccccct tcagccccag cctcacctgt 4920
 ttagttagaag ctggagctgc tttctctgg gccctcagtag tgcctctgtt ggccttca 4980
 tgtcggcttc ggggagctat gggcgtggg aaacagctgg tggccttctt agactatgga 5040
 gaagaggaca gttaggcaga cagtagcaag agggatcaca tctgaagcca ggtgtcttgt 5100
 cctctcagag ctgagtggac cttgtaagtc aacgtgcaac ctgctcccc tcccaactct 5160
 gggccagatc ctccccctcc caacagttcc catccatggg tcaggecctt ggagagaggg 5220
 aaagagaggg ggaagtgagg gaaggagaga gaaggctccc tttagtctt ggtgagctgg 5280
 gcctgacctg agcacagctc tggagtaaca cccaggagcc acccgcctca cctcaggagt 5340
 tccagggccc tgggtgggct ctaggagac ccgtttgcgc tgcctccggg tggtagtccc 5400
 agtgcctctg getatctgga ttggctgcat gctggctcgg cgcagggctc cttgggggtc 5460
 tccagtttcc atctcctcat ctgtgatggt gcccaggctc agggaaaggt ccatgggtgg 5520
 aagaggtggt cagtggacca tagctgtat gagatggagg aggacctggg gctgttccag 5580
 aactctacac tcgcccgaca cttatggctg ggacccttcc tgcctacgag gtagaagac 5640
 acaagcctcc tttcctgttc tgctttctac ctaagcctg ggcaaatggc acaagcagtg 5700
 cagtcctgac cagattcttc tctgagctcc tgcctacccc cagggacttc acccctgagt 5760
 gccctccagc tgtctgttcc acctggaaca tgagaaggtc accccttccc ctctcggccc 5820
 agtcagtgat ccagggccct agtgcctcag ctatgacagc aggtgggatt ccaaggaagg 5880

gcagggatgg gagccctgc acagtgacct caggcctcac cctggactcc agggatagca 5940
 ggtcttcaga tgtggggggc acactcgatt gcgctgctgc agctctgcaa tgcggttcca 6000
 gtcattccagc tgctcaggct catcctggca agtgcccatg tagaagctgt tccttctctgt 6060
 ggaaggcagg gaagtgggaa caaatgagcc tggagtcggc aggtcacctc ctggccctgg 6120
 catcttgcca gcctttgctg ccacctaccc cataaacctg aagcccggca caccagctcg 6180
 attcagtgcc gcaggtgcag gagtacggca cacagactat ttctatccta ggggcttctgt 6240
 caccaccctc tccttgaga gggcagaaga ggtcacacgc agagactgct actacatctt 6300
 attcacctgc caagccttgg tggccaacac ccagaggaac aaattaagga ccgggaatta 6360
 attcccaggg gctccctggt gcccaaaagg caagagcttc caagaagagt ctggccagcc 6420
 tggcctttcc agcagcccat caccgcctga gaagggcctg gaggactccc cacagctaaag 6480
 tgtcacaatt tgctgggaa tcccgggccc ttaactctgg ctaagagtgc cccaacaca 6540
 gccagccctc agatgggcag gtaaggaagg ccctgaggct gcaggaagga ggggcagggtg 6600
 gagctggatg gtagcaagga ggcagcctt ggatttttaa aaagctttcc tcttttccct 6660
 gtgccacgat ccacctcca gtctaatttt ggggtatagt aagtcctctg agtcccctca 6720
 cctggagggg cccactgga caccocggcc tgggaacgac gaggagaact gcgagtgggtg 6780
 gggcggtagc caggcaagct gaggcaggct gaggttccat aatcgggaga acccaggcga 6840
 gctagagact gagttagagga ggtggctcgc aggttagcct gggaaagcagg agcagaccgc 6900
 gtgctgtaga acgatgagtt ggcgctgtct ggctcttcca catctagctt ctggaagaca 6960
 gagtgaatct gttgcagtgt acagtccctg gcactgtaca gaagcttccc attcccctcc 7020
 gaagccctca gatccacagg cacatccatg tattcccaac tgctttgcaa aggtccctaa 7080
 agtgtgtgct tgcaagaaat gggccttgtc gacagaagcc ctcacaaggt ggtgctgatg 7140
 ttgtcaagac tcttctacgc attttttca tggagtctat tcataatgct ttgaggtagg 7200
 gaatgcagag tgtttatcgg cccattttgg agatgaagtg caaagaaata aagtgactag 7260
 ccccaaatca cactgctagg aagtatcaga gctggggcta ggcccatgt ctcctgacta 7320
 gtcaggctca tcccacagcc tctgctgtcc ctacgtccaa acttccaggg cccttaccat 7380
 gttccagaac tcccccaac ttcttgtagt caggggggcac cctaaacaca caggtccccc 7440
 ctgctgtacc aggggcccc tctcccctcc tcccacaacct ccccttcaag atgtggaaac 7500
 aaagccaagg gcctgcagcc tgtcaggcag tccactgggc agcaacaatg cctctcagct 7560
 gcatggggca tgctgggagg cacaggatgg gctgcagctt cggcacgttc tctcccttca 7620
 cctgcacag gctcagtgct acgcatggag agaatgctag ccttagtcag gaggcaggga 7680
 tctaattcca gccctgcctt tttcttcaga agtgccctta accaagtcac tgcccttttt 7740
 aagacccttc agctttccca ctgtaacatg gactggctgc tcacccctcc ctgctcctga 7800
 ctgagtgccc ag 7812

<210> 10
 <211> 40
 <212> PRT
 <213> Homo sapiens

<400> 10
 Thr Pro Val Ser Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser
 1 5 10 15
 Thr Lys Asp Pro Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys
 20 25 30
 Gln Cys Pro Ala Leu Glu Val Thr
 35 40

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence selected from the group consisting of AA1-
5 AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA112 of SEQ ID
NO:4 AA29-AA112 of SEQ ID NO:4 AA1-AA197 of SEQ ID NO:6, AA29-AA197
of SEQ ID NO:6, AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID
NO:8,

(b) a mutein of any one of the sequences in (a), wherein the amino
10 acid sequence of said mutein has at least 40% identity to at least one of the
sequences in (a).

2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence selected from the group consisting of AA1-
15 AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA197 of SEQ ID
NO:6, and AA29-AA197 of SEQ ID NO:6,

(b) a mutein of any one of the sequences in (a), wherein the amino acid
sequence of the said mutein has at least 40% identity to at least one of the
sequences in (a);

20 wherein the polypeptide of (a) or (b) binds to IL-18.


3. The polypeptide of claim 1 or 2 wherein the amino acid sequence of the
mutein of (b) has at least 50% identity to at least one of the sequences in (a).

4. The polypeptide of any one of claims 1 to 3, wherein the amino acid
sequence of the mutein of (b) has at least 60% identity to at least one of the
25 sequences in (a).

5. The polypeptide of any one of claims 1 to 4, wherein the amino acid
sequence of the mutein of (b) has at least 70% identity to at least one of the
sequences in (a).

6. The polypeptide of any one of claims 1 to 5, wherein the amino acid
30 sequence of the mutein of (b) has at least 80% identity to at least one of the
sequences in (a).

7. The polypeptide of any one of claims 1 to 6, wherein the amino acid
residues in the mutein of (b) have at least 90% identity to at least one of the
sequences in (a).



8. The polypeptide of any one of the previous claims, wherein any changes in the amino acid residues in the mutein of (b) are conservative amino acid substitutions to the amino acid sequences in (a).
9. The polypeptide of any one of the previous claims, wherein the amino acid sequence comprises AA1-AA192 of SEQ ID NO:2 or AA29-AA192 of SEQ ID NO:2.
10. The polypeptide of any one of the previous claims, wherein the polypeptide is glycosylated at one or more sites.
11. The polypeptide of any one of claims 1 to 9, wherein the polypeptide is not glycosylated.
12. The polypeptide of any one of the previous claims, wherein the polypeptide further comprises at least one moiety attached to one or more functional groups which occur as one or more side chains on the amino acid residues or the N- or C-terminal groups.
13. The polypeptide of any one of the previous claims, wherein the polypeptide is circularly permuted.
14. The polypeptide of any one of the previous claims, wherein the polypeptide is a non-viral protein.
15. The polypeptide of claim 15, wherein the polypeptide is a human protein.
16. The polypeptide of any one of the previous claims, wherein the polypeptide is a fused protein.
17. The polypeptide of claim 16 wherein the polypeptide comprises an Ig fusion.
18. The polypeptide of any one of the previous claims, wherein the polypeptide is soluble.
19. The polypeptide of claim 1, wherein the polypeptide is pegylated.
20. The polypeptide of claim 12, wherein said at least one moiety is a polyethylene glycol moiety.
21. An isolated polypeptide comprising the amino acid sequence of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, or conservative amino acid substituents thereof.
22. An isolated polypeptide comprising the amino acid sequence of AA1-AA112 of SEQ ID NO:4 AA29-AA112 of SEQ ID NO:4 or conservative amino acid substituents thereof.




23. An isolated polypeptide comprising the amino acid sequence of AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6, or conservative amino acid substituents thereof.
24. An isolated polypeptide comprising the amino acid sequence of AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID NO:8, or conservative amino acid substituents thereof.
25. An isolated polypeptide that includes the amino acid sequence of AA29-40 of SEQ ID NO:2 or AA1-AA40 of SEQ ID NO: 10, wherein the polypeptide binds to IL-18 and modulates or blocks the biological activity of IL-18.
26. The polypeptide of claim 25, wherein the polypeptide contains an Ig domain.
27. A purified IL-18 binding protein (IL-18 BP), wherein the protein is characterized as follows:
- (a) the protein has a molecular weight of about 40 kD as measured by SDS-PAGE in its originally glycosylated form;
 - (b) the protein binds to IL-18, and modulates or blocks the activity of IL-18; and
 - (c) the protein has an N-terminal sequence that includes the amino acid sequence of AA29-40 of SEQ ID NO:2 or AA1-AA40 of SEQ ID NO:10, or conservative amino acid substituents thereof.
28. An active fragment of the IL-18 BP protein of any one of the previous claims, wherein the active fragment binds to IL-18, and modulates or blocks the activity of IL-18.
29. An isolated IL-18 BP polypeptide having an N-terminal sequence that includes the amino acid sequence of AA29-40 of SEQ ID NO:2 or AA1-AA40 of SEQ ID NO: 10, or conservative amino acid substituents thereof, and an Ig domain, wherein the polypeptide binds to IL-18, and modulates or blocks the activity of IL-18.
30. A mixture of any of the polypeptides according to claims 1, 2, 21-25, 27 or 28.
31. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of
- (a) an amino acid sequence selected from the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA112 of



SEQ ID NO:4 AA29-AA112 of SEQ ID NO:4 AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6, AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID NO:8,

- (b) a mutein of any one of the sequences in (a), wherein the amino acid sequence of said mutein has at least 40% identity to at least one of the sequences in (a).
- 5
32. The isolated nucleic acid molecule of claim 31 wherein the amino acid sequence of the mutein has at least 80% identity to at least one of the sequences in (a).
- 10
33. The isolated nucleic acid molecule of claim 31 wherein the amino acid sequence of the mutein has at least 90% identity to at least one of the sequences in (a).
34. An isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of:
- 15
- (a) a nucleic acid sequence of SEQ ID NO: 1 encoding AA1-AA192 of SEQ ID NO:2 or AA29-AA192 of SEQ ID NO:2
- (b) a nucleic acid sequence of SEQ ID NO: 3 encoding AA1-AA112 of SEQ ID NO:4 or AA29-AA112 of SEQ ID NO:4;
- 20
- (c) a nucleic acid sequence of SEQ ID NO: 5, encoding AA1-AA197 of SEQ ID NO:6 or AA29-AA197 of SEQ ID NO:6;
- (d) a nucleic acid sequence of SEQ ID NO: 7, encoding AA1-AA161 of SEQ ID NO:8, or AA29-AA161 of SEQ ID NO:8;
- 25
- (e) a nucleic acid sequence whose complement binds, under high stringency conditions, to any one of the nucleic acid sequences in (a) through (d) and which encodes an amino acid sequence selected from the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA112 of SEQ ID NO:4 AA29-AA112 of SEQ ID NO:4 AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6, AA1-AA161 of SEQ ID NO:8, and AA29-AA161 of SEQ ID NO:8.
- 30
35. An isolated nucleic acid molecule containing the nucleic acid sequence of SEQ ID NO: 9, or a nucleic acid sequence whose complement binds, under high stringency conditions, thereto.
36. An isolated nucleic acid molecule comprising a nucleotide sequence
- 35
- selected from the group consisting of SEQ ID NO: 1, 3, 5, and 7 or a mature protein encoding portion of any one of SEQ ID NO: 1, 3, 5, and 7.



37. A DNA primer having a nucleotide sequence selected from the group consisting
- (a) TATATCTAGAGCCACCATGAGACACAACCTGGAACCA, and
- (b) ATATCTAGATTAATGATGATGATGATGATGATGACCCCTGCTGCTGTGGACTGC
- 5 38. A method for identifying, isolating or amplifying an IL-18 BP encoding nucleic acid sequence, comprising using the isolated nucleic acids of any one of claims 31 to 37 as a primer or probe.
39. A vector comprising the nucleic acid molecule of any one of claims 31 - 36.
- 10 40. The vector of claim 39, further comprising a promoter operably-linked to said nucleic acid molecule.
41. A cell that has been genetically modified to produce a polypeptide according to any one of claims 1-29.
42. The cell of claim 41, wherein the cell has been genetically modified to
- 15 contain the vector of claim 39.
43. The cell of claim 41 or 42, wherein the cell is eukaryotic.
44. The cell of claim 41 or 42, wherein the cell is prokaryotic.
45. The cell of claim 43, wherein the cell is mammalian.
46. A method for production of the polypeptide of any one of claims 1-29,
- 20 comprising culturing the cell of any one of claims 41 to 45, under conditions suitable for expression of said polypeptide.
47. An antibody that immunospecifically-binds to the polypeptide of any one of claims 1 - 29.
48. The antibody of claim 47, wherein said antibody is a monoclonal
- 25 antibody.
49. The antibody of claim 48, wherein the antibody is a humanized antibody.
50. A method for detecting an IL-18 BP in a sample, comprising contacting said sample with an antibody of any one of claims 45 to 47 and further detecting the presence of bound antibody.
- 30 51. A method for purifying an IL-18 BP polypeptide, comprising contacting an IL-18 BP sample with an IL-18 BP antibody of any one of claims 47 to 49, removing unbound protein in the sample and then eluting the bound IL-18 BP.
52. A process for the isolation or purification of an IL-18 BP according to any one of claims 2 - 29, comprising:
- 35 (a) passing a sample through a chromatographic column to which IL-18 is coupled;



- (b) washing the column to remove unbound protein in the sample, and
- (c) eluting the bound IL-18 BP.

53. A process for the isolation or purification of an IL-18 BP according to any one of claims 2 - 29, comprising contacting a sample with a substrate to
5 which IL-18 is coupled, removing unbound protein in the sample and then eluting the bound IL-18 BP.

54. A method for the preparation of an IL-18 BP derivative comprising preparing a DNA construct that encodes a polypeptide according to claims 1, 2, 21-25, and 27-29, ligated to a nucleic acid encoding a second polypeptide,
10 wherein on expression, said DNA construct encodes a fusion protein comprising the polypeptide of any one of claims 1, 2, 21-25, and 27-29, fused to the second polypeptide.

55. The method of claim 54, wherein the second polypeptide is Ig.

56. A method for the preparation of an IL-18 BP derivative comprising
15 chemically modifying a polypeptide according to any one of claims 1, 2, 21-25, to include at least one derivative moiety.

57. The method of claim 56, wherein the derivative moiety is a polyethylene glycol moiety.

58. A composition comprising the polypeptides of any one of claims 1- 30
20 and a pharmaceutically-acceptable carrier.

59. A composition comprising the nucleic acid molecule of any one of claims 31 - 36 and a pharmaceutically-acceptable carrier.

60. A composition comprising the antibody of any one of claims 47 - 49 and a pharmaceutically-acceptable carrier.

25 61. A kit, comprising in one or more vials, the pharmaceutical composition of claim 58.

62. A kit, comprising in one or more vials, the pharmaceutical composition of claim 59.

30 63. A kit, comprising in one or more vials, the pharmaceutical composition of claim 60.

64. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

35 (a) an amino acid sequence selected from the group consisting of AA1-AA192 of SEQ ID NO:2, AA29-AA192 of SEQ ID NO:2, AA1-AA197 of SEQ ID NO:6, AA29-AA197 of SEQ ID NO:6,



(b) a mutein of any one of the sequences in (a), wherein the amino acid sequence of said mutein has at least 40% identity to at least one of the sequences in (a);

wherein said nucleic acid molecule encodes for a polypeptide that binds IL-18.

65. The isolated nucleic acid of claim 64 wherein the mutein has at least 80% identity to at least one of the sequences in (a).

66. The isolated nucleic acid of claim 64 wherein the mutein has at least 90% identity to at least one of the sequences in (a).

67. An isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence of SEQ ID NO: 1 encoding AA1-AA192 of SEQ ID NO:2 or AA29-AA192 of SEQ ID NO:2


(b) a nucleic acid sequence of SEQ ID NO: 5, encoding AA1-AA197 of SEQ ID NO:6 or AA29-AA197 of SEQ ID NO:6;

(c) a nucleic acid sequence whose complement binds, under high stringency conditions, to any one of the nucleic acid sequences in (a) through (c); wherein said nucleic acid encodes a polypeptide that binds IL-18.

68. A recombinant DNA molecule comprising the nucleic acid molecule according to claim 62 or 63, ligated to a second nucleic acid encoding a second polypeptide wherein on expression, said DNA construct encodes a fusion protein comprising the polypeptide of any one of claims 1, 2, 21-25, and 27-29, fused to the second polypeptide.

69. A method of treating or preventing a disease associated with an excess of IL-18, said method comprising administering to a subject in which such treatment or prevention is desired, the composition of claims 58, 59 or 60 in an amount sufficient to treat or prevent said disease in said subject.

70. A method of treating or preventing a disease selected from the group consisting of autoimmune diseases, Type 1 diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease, ischemic brain injury, chronic hepatitis, acute hepatitis, psoriasis, chronic pancreatitis, and acute pancreatitis, said method comprising administering to a subject in which such treatment or prevention is desired, the composition of claims 58 or 59 in an amount sufficient to treat or prevent said disease in said subject.



71. The method of claim 69 or claim 70, wherein the disease is rheumatoid arthritis.
72. The method of claim 69 or claim 70 wherein, the disease is chronic or acute hepatitis.
- 5 73. The method of claim 69 or claim 70 wherein the disease is inflammatory bowel disease.
74. The method of claim 69 or claim 70, wherein the disease is psoriasis.
75. The method of claim 67 - 70, wherein said subject is a human.
76. Use of a polypeptide of any one of claims 1 to 30 in the
10 manufacture of a pharmaceutical composition for use in treating or preventing a disease selected from the group consisting of autoimmune diseases, Type 1 diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease, ischemic brain injury, chronic hepatitis, acute hepatitis, psoriasis,
15 chronic pancreatitis, and acute pancreatitis.
77. Use of a nucleic acid molecule of any one of claims 31 to 36 in the manufacture of a pharmaceutical composition for use in treating or preventing a disease selected from the group consisting of autoimmune diseases, Type 1 diabetes, rheumatoid arthritis, graft rejections,
20 inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease, ischemic brain injury, chronic hepatitis, acute hepatitis, psoriasis, chronic pancreatitis, and acute pancreatitis.
78. The use of claim 76 or claim 77, wherein the disease is inflammatory bowel disease.
- 25 79. The use of claim 76 or claim 77, wherein the disease is psoriasis.



DATED this 23rd day of October 2002

Yeda Research & Development Co Ltd
Patent Attorneys for the Applicant:

F.B. RICE & CO.






FIG. 1




FIG. 2




FIG. 3a

4/25






Fig. 3 B-D

5/25




Fig. 3E

6/25

IL-18Bpa; DNA sequence:

Length: 1348 December 14, 1997 15:41 Type: N Check: 2207 ..

```
1 GAGAAGAGGA CGTTGTCACA GATAAAGAGC CAGGCTCACC AGTCCTGAC
51 GCATGCATCA TGACCATGAG ACACAACCTGG ACACCAGACC TCAGCCCTTT
101 GTGGGTCTCG CTCCTGTGTG CCCACGTCGT CACTCTCCTG GTCAGAGCCA
151 CACCTGTCTC GCAGACCACC ACAGCTGCCA CTGCCTCAGT TAGAAGCACA
201 AAGGACCCCT GCCCCTCCA GCCCCAGTG TTCCAGCAG CTAAGCAGTG
251 TCCAGCATTG GAAGTGACCT GGCCAGAGGT GGAAGTGCCA CTGAATGGAA
301 CGCTGAGCTT ATCCTGTGTG GCCTGCAGCC GCTTCCCCAA CTTCAGCATC
351 CTCTACTGGC TGGGCAATGG TTCCTTCATT GAGCACCTCC CAGGCCGACT
401 GTGGGAGGGG AGCACCAGCC GGAACGTGG GAGCACAGGT ACGCAGCTGT
451 GCAAGGCCTT GGTGCTGGAG CAGCTGACCC CTGCCCTGCA CAGCACCAAC
501 TTCTCCTGTG TGCTCGTGGG CCTGAACAG GTTGTCAGC GTCACGTCGT
551 CCTGGCCCAG CTCTGGGCTG GGCTGAGGGC AACCTTGCCC CCCACCCAAG
601 AAGCCCTGCC CTCCAGCCAC AGCAGTCCAC AGCAGCAGGG TTAAGACTCA
651 GCACAGGGCC AGCAGCAGCA CAACCTTGAC CAGAGCTTGG GTCCTACCTG
701 TCTACCTGGA GTGAACAGTC CCTGACTGCC TGTAGGCTGC GTGGATGCGC
751 AACACACCCC CTCCTTCTCT GCTTTGGGTC CCTTCTCTCA CCAAATTCAA
801 ACTCCATTCC CACCTACCTA GAAAATCACA GCCTCCTTAT AATGCCTCCT
851 CCTCCTGCCA TTCTCTCTCC ACCTATCCAT TAGCCTTCCT AACGTCCTAC
901 TCCTCACACT GCTCTACTGC TCAGAAACCA CCAAGACTGT TGATGCCTTA
951 GCCTTGCACT CCAGGGCCCT ACCTGCATTT CCCACATGAC TTTCTGGAAG
1001 CCTCCCAACT ATTCTTGCTT TTCCAGACA GCTCCCACTC CCATGTCTCT
1051 GCTCATTTAG TCCCCTCTC CTCACCGCCC CAGCAGGGGA ACGCTCAAGC
1101 CTGGTTGAAA TGCTGCCTCT TCAGTGAAGT CATCCTCTTT CAGCTCTGGC
1151 CGCATTCTGC AGACTTCCTA TCTTCGTGCT GTATGTTTTT TTTTCCCCC
1201 TTCACTCTAA TGGACTGTTT CAGGGAAGGG ATGGGGGCAC CAGCTGCTTC
```

Fig. 4

7/25

1251 GGATCCACAC TGTATCTGTG TCATCCCCAC ATGGGTCCTC ATAAAGGATT

1301 ATTCAATGGA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

(SEQ ID NO:1)

IL-18Bpa; Protein sequence:

Length: 192 June 5, 1998 13:39 Type: P Check: 3073 ..

1 MRHNWTPDLS PLWVLLCAH VVTLVLRATP VSQTTAATA SVRSTKDPCP

51 SQPPVFPAK QCPALEVTPW EVEVPLNGTL SLSCVACSRF PNFSILYWLG

101 NGSFIEHLPG RLWEGSTSRE RGSTGTQLCK ALVLEQLTPA LHSTNFCVL

151 VDPEQVVQRH VVLAQLWAGL RATLPPTQEA LPSSHSPQQ QG

(SEQ ID NO:2)

Fig. 4A

IL-18BPb; DNA sequence

Length: 1038 June 19, 1998 14:10 Type: N Check: 8005 ..

1 GAGAAGAGGA CGTTGTCACA GATAAAGAGC CAGGCTCACC AGCTCCTGAC
51 GCATGCATCA TGACCATGAG ACACA ACTGG ACACCAGACC TCAGCCCTTT
101 GTGGGTCCTG CTCCTGTGTG CCCACGTCGT CACTCTCCTG GTCAGAGCCA
151 CACCTGTCTC GCAGACCACC ACAGCTGCCA CTGCCTCAGT TAGAAGCACA
201 AAGGACCCCT GCCCCTCCCA GCCCCCAGTG TTCCAGCAG CTAAGCAGTG
251 TCCAGCATTG GAAAGTGACCT GGCCAGAGGT GGAAGTGCCA CTGAGCTGGG
301 CTGAGGGCAA CCTTGCCCC CACCCAAGAA GCCCTGCCCT CCAGCCACAG
351 CAGTCCACAG CAGCAGGGTT AAGACTCAGC ACAGGGCCAG CAGCAGCACA
401 ACCTTGACCA GAGCTTGGGT CCTACCTGTC TACCTGGAGT GAACAGTCCC
451 TGA CTGCCTG TAGGCTGCGT GGATGCGCAA CACACCCCTT CCTTCTCTGC
501 TTTGGGTCCC TTCTCTCACC AAATTCAAAC TCCATTCCCA CCTACCTAGA
551 AAATCACAGC CTCCTTATAA TGCCTCCTCC TCCTGCCATT CTCTCTCCAC
601 CTATCCATTA GCCTTCCTAA CGTCCTACTC CTCACACTGC TCTACTGCTC
651 AGAAACCACC AAGACTGTTG ATGCCTTAGC CTTGCACTCC AGGGCCCTAC
701 CTGCATTTC CACATGACTT TCTGGAAGCC TCCCAACTAT TCTTGCTTTT
751 CCCAGACAGC TCCACTCCC ATGTCTCTGC TCATTTAGTC CCGTCTTCCT
801 CACCGCCCA GCAGGGGAAC GCTCAAGCCT GGTGAAATG CTGCCTCTTC
851 AGTGAAGTCA TCCTCTTTCA GCTCTGGCCG CATTCTGCAG ACTTCCTATC
901 TTCGTGCTGT ATGTTTTTTT TTTCCCCTT CACTCTAATG GACTGTTC A
951 GGAAGGGAT GGGGGCACCA GCTGCTTCGG ATCCACACTG TATCTGTGTC
1001 ATCCCCACAT GGGTCCTCAT AAAGGATTAT TCAATGGA

(SEQ ID NO:3)

Fig. 5

WO 99/09063

PCT/IL98/00379

9/25

huL-18BPb
Clone-m7
peptide

1 MRHNWTPD LSPLWVLLC AHVVTLVRA TPVSQITTA TASVRSTKDP
49 CPSQPPVFP AAKQCPALEVT WPEVEVPLSW AEGNLAPHPR SPALQPQQST
99 AAGLRLSTGP AAAQP*

(SEQ ID NO: 4)

Fig. 5A

10/25

huL18BPc.seq Length: 7063 July 16, 1998 19:47 Type: N Check: 9314 ..

1 GAATTCGCGG CCGCGTCGAC GCCAGAGGGG CTAGGATGAG AGACAGAGGG
51 TGTGATGGTG GGTGCTGGGA AATGTACCCG ACCTTGGGGC TGGTGGCTGG
101 GGGAGTGGGT AGCCTGGGAA AGGCCAGGAT GTGGACGGAC TGGTATGGCA
151 TTGAGCCTGA AGTGGTCCAA CTTGGGGTTC CCCAGTGCCT AGGAAAGTTG
201 TCCCCTTGAA TGTCAGTGTG AAGGTGAAGG AGGAAGCAGA TGCCTGTTC
251 TATGAAACA AAGACCTGGC TGTGAAGAGG GGAGGCGGAC ACCAAAGTCC
301 TGACACTTGG GCGGACAGA ATTGATCTGT GAGAGACTCA TCTAGTTCAT
351 ACCCTAGGTG ACCCTGGGGG TGGCATGGGG GTAGATTAGA GATCCCAGTC
401 TGGTATCCTC TGAGAGTAG GAGTCCCAGG AGCTGAAGGT TTCTGGCCAC
451 TGAAC TTTGG CTAAAGCAGA GGTGTCACAG CTGCTCAAGA TTCCTGGTT
501 AAAAAAGTGAA AGTGAATAG AGGGTCGGGG CAGTGCTTTC CCAGAAGGAT
551 TGCTCGGCAT CCTGCCCTTC CCAGAAGCAG CTCTGGTGCT GAAGAGAGCA
601 CTGCCTCCCT GTGTGACTGG GTGAGTCCAT ATTCTCTCTT TGGGTCTCAA
651 TTTGCCTTC CCTAATGAAG GGGTAAGATT GGAAGGATTG AGCATCTTAC
701 AACCATTTGT GGTGATGAGA GCTGGGGTGG GGAAGGATTG TCACTTGACC
751 CCCCAGCTC TGTTTCTAAG TGCTGAAAGA GCTCCAGGCT ATGCTACGGG
801 AGGAGAAGCC AGTACTGAG GAAAAGCCAG CTACTGAGAA AAAGCGGGAG
851 TGGTTTACCA TTCTCCTCCC CCACCTTTC CAAGAGAAGA GGACGTTGTC
901 ACACATAAAG AGCCAGGCTC ACCAGCTCCT GACGCATGCA TCATGACCAT
951 GAGACACAAC TGGACACCAG ACCTCAGCCC TTTGTGGGTC CTGCTCCTGT
1001 GTGCCACGT CGTCACTCTC CTGGTCAGAG CCACACCTGT CTCGCAGACC
1051 ACCACAGCTG CCACTGCCTC AGTTAGAAGC ACAAAGGACC CCTGCCCTC
1101 CCAGCCCCCA GTGTTCCAG CAGCTAAGCA GTGTCCAGCA TTGGAAGTGA
1151 CCTGGCCAGA GGTGGAAGTG CCACTGAATG GAACGCTGAG CTTATCCTGT
1201 GTGGCCTGCA GCCGCTTCCC CAACTTCAGC ATCCTCTACT GGCTGGGCAA

Fig. 6

11/25

1251 TGGTTCCTTC ATTGAGCACC TCCCAGGCCG ACTGTGGGAG GGGAGCACCA
1301 GCCGGGAACG TGGGAGCACA GGTACGCAGC TGTGCAAGGC CTTGGTGCTG
1351 GAGCAGCTGA CCCCTGCCCT GCACAGCACC AACTTCTCCT GTGTGCTCGT
1401 GGACCCTGAA CAGGTTGTCC AGCGTCACGT CGTCCTGGCC CAGCTCTGGG
1451 TGAGGAGCCC AAGGAGAGGC CTCCAGGAAC AGGAGGAGCT CTGCTTCCAT
1501 ATGTGGGGAG GAAAGGGTGG GCTCTGCCAG AGCAGCCTGT GAACTAATGC
1551 CCAGCATTCC TCAAGGTCAG CCAGACAAA AGGAACTTAG GTCTTGGGCA
1601 GAGGAGGTGT AGCCTGGGGC AAAGTGATGA GATGTCCCTC CTTTCTTGG
1651 CCTGATCCTT GTCTGCCTTC ACTTCCCTAG GCTGGGCTGA GGGCAACCTT
1701 GCCCCCCACC CAAGAAGCCC TGCCCTCCAG CCACAGCAGT CCACAGCAGC
1751 AGGGTTAAGA CTCAGCACAG GGCCAGCAGC AGCACAACCT TGACCAGAGC
1801 TTGGGTCCTA CCTGTCTACC TGGAGTGAAC AGTCCCTGAC TGCCTGTAGG
1851 CTGCGTGGAT GCGCAACACA CCCCTCCTT CTCTGCTTTG GGTCCCTTCT
1901 CTCACAAAT TCAAACCTCA TTCCACCTA CCTAGAAAAT CACAGCCTCC
1951 TTATAATGCC TCCTCCTCCT GCCATTCTCT CTCCACCTAT CCATTAGCCT
2001 TCCTAACGTC CTACTCCTCA CACTGCTCTA CTGCTCAGAA ACCACCAAGA
2051 CTGTTGATGC CTTAGCCTTG CACTCCAGGG CCCTACCTGC ATTTCCACACA
2101 TGACTTTCTG GAAGCCTCCC AACTATTCTT GCTTTTCCCA GACAGCTCCC
2151 ACTCCCATGT CTCTGCTCAT TTAGTCCCGT CTTCCTCACC GCCCCAGCAG
2201 GGGAAAGGCTC AAGCCTGGTT GAAATGCTGC CTCTCAGTG AAGTCATCCT
2251 CTTTCAGCTC TGGCCGCATT CTGCAGACTT CCTATCTTCG TGCTGTATGT
2301 TTTTTTTTTC CCCCTTCACT CTAATGGACT GTTCCAGGGA AGGGATGGGG
2351 GCAGCAGCTG CTTCCGATCC AACTGTATC TGTGTCATCC CCACATGGGT
2401 CCTCATAAAG GATTATTCAA TGGAGGCATC CTGACATCTG TTCATTTAGG
2451 CTTCAGTCC ACTCCAGGA ACTTTGCCTG TCCCACGAGG GAGTATGGGA
2501 GAGATGGACT GCCACACAGA AGCTGAAGAC AACACCTGCT TCAGGGGAAC

Fig. 6A

12/25

2551 ACAGGCGCTT GAAAAAGAAA AGAGAGAACA GCCCATAATG CTCCCCGGGA
2601 GCAGAGGCCA CTAATGGAGA GTGGGAAGAG CCTGGAAAGA TGTGGCCTCA
2651 GGAAAAGGGA TGAGAGAAAAG GAGGTGGTAT GGAAGACTCA GCAGGAACAA
2701 GGTAGGCTTC AAAGAGCCTA TATTCCTCTT TTCCACAC CGATCAAGTC
2751 AACTCAGTAC TCACGGGAGA AAAATAGACT TTATTTACAA GTAATAACAT
2801 TTAGAAAAGA TCCATCCCCG GCCCTTAAAA ACCTTCCCAT CACTCCAAAT
2851 CCCACCCAG TGCAAGTCTG GGAAGGTAG GGTGTGAGCT GCTGCTGAAG
2901 GCTGTCCCC AACCCACTC CTGAGACACA GGGCCATCC GTCCTGGAA
2951 AGAGCATCCT CTGGCAGGTG CTCCACCAG GTCAGACCA GTCCTGGACT
3001 TCAAGAGTGA GGGCCCTGC TGGGCCAGC CACCAGGACA GCAGGAACCA
3051 GGGCCTACTC CTCTTATGGT CCCTTCTAGA TCCAGAGGCT AAGAGGAAGA
3101 CTGGCCAGGC CCAAGGACCC AGCCATCAAA ACCAGCCTCA AATCTGGTTG
3151 TGATGGAGAA GTGACTTTGC TTTAAGAAAA AAGGAGGCAA GGTAGGGAGA
3201 GCGCCACAC TGTCATGCT CCAGCCCCC TGGGCCAGCT CCGAGAAGGC
3251 GCCAGTGAAG GACCAGGGAC CAGGCCAGG TCGGGCAGG CATCACTGTC
3301 TCTAGGGTT TGGCTACTGT TGGCCTGGA GCTGAGAGAA GGCCTGAGA
3351 GGGACAGTAG GCGGAGGACC AGGTGACGGC AGCATCGGGG ACACAGGTGG
3401 GGCCACTCAC TGTTACTGGC CCTTTAGTGC TTTGCCTGAA AGAGACACAG
3451 TCACATGGCC AGATGAGAAC TTGCGATACT AGCCTGCACC CACTGGCTGG
3501 GAAGATCTCT TCCTGTCCC ACGCCCCTGT CTGGATCCCC TCCCTGTGA
3551 GCCCCAGGGT TATCAGTTGC TGGCTGTGCC TGAGCAGCTC TGGGTGCTCT
3601 CCATGAGAAT GGGGCCATCT GTCTTCTCTC CTTGGAGAGG AGTACCAGG
3651 ACAGGGACAC CTCTTACCCC ACACCCTCCA GCAGCCTGGC GTGGCCCCAT
3701 CTTGGATGCT ACTTGGTGGG GCGGTCTGGG GGGTGCCAT GCTCTCATCG
3751 GGTTCCTC CCCCATCCTG CCAAGTGCCTC TACCTTGCCC TTGGCTCGAG
3801 GGGTGGCACC AATGGCGGCA GCAGTGGCGG CGCTGGCTGT GGTGGTGGCA

Fig. 6B

3851 ATGCGCGGAG AACGGCGGGT TCCACTGCGA GTGTTGGGGG AAGCCTTGG
3901 CAGGGCCTTC TTTGAGGCTC CCCGCCGAG AAGGCTGTTC CCTAGCTTCT
3951 TGGGTGTGTT GAGGATGCTG AAGGCCATCG ACTGGCGCCG GTCAGCCTGC
4001 AAGGAAGGGC TGTCAGACCG GGAGACCCAA TGCTGCCTTC CCAGGCCAGC
4051 GTGCTGTGCC ACGCTGTACC AGCAAGGTCC CGCCAGGGCG TCGCTTCATC
4101 CCCCTTCAGC CCCAGCCTCA CCTGTTTGTG AGAAGCTGGA GCTGCTTTCT
4151 TCTGGGCTC AGTAGTGCTC TGTTTGGGCC CTTCATGTGC GTCTCGGGGA
4201 GTCATGGGGC GTGGGAAACA GCTGGTGGCC TTCTTAGACT ATGGAGAAGA
4251 GGACAGTTAG GCAGACAGTA GCAAGAGGAG TCACATCTGA AGCCAGGTGT
4301 CTTGCTCTCT CAGAGCTGAG TGGACCTGT AAGTCAACGT GCAACCTGCT
4351 CCCCTTCCA ACTCTGGGCC AGATCCTTCC CTTCCTCAACA GTTCCCATCC
4401 ATGGGTCAGG CCCTTGGAGA GAGGGAAAGA GAGGGGAAG TGAGGGAAGG
4451 AGAGAGAAGG CTCCTTTAG TCCTTGGTGA GCTGGGCTG ACCTGAGCAC
4501 AGTGCTGGAG TAACACCCAG GAGCCACCGC GCCTACCTCA GGAGTTCCAG
4551 GGCCTGGTG GGGCTCTAGG GAGACCCGTT TGCCTGCTG CCGGGTGGTG
4601 ATGCCAGTGC CCTCGGCTAT CTGGATTGGC TGCATGCTGG CTCGGCGCAG
4651 GGTCTCTGG GGGTCTCCAG TTTTCATCTC CTCATCTGTG ATGGTGCCCA
4701 GGCTCAGGA AGGCTGCATG GGTGGAAGAG GTGGTCAGTG GACCATAGCT
4751 GTATGGAGAT GGAGGAGGAC CTGGGGCTGT TCCAGAACTC TACTCTGCC
4801 CGACACTTAT GGTCCGGACC CTTCCTGCCT ACGAGGTAGA AAGACACAAG
4851 CCTCCTTCC TGTCTGCTT TCTACCTAAG CCCTGGGCAA ATGGACAAG
4901 CAGTGACGTC CTGACCAGAT TCCTCTCTGA GCTCCTGCCT ACCCCAGGG
4951 ACTTACCCC TGAGTGCCCT CCAGCTGTCT GTTCCACCTG GAACATGAGA
5001 AGGTCACCCC TTCCCCTCTT CGGCCAGTCA GTGATCCAGG GCCCTAGTGC
5051 TCAGGCTAGA TCAGCAGGTG GGATTCCAAG GAAGGGCAGG GATGGGAGGC
5101 CCTGCACAGT GACCCAGGC CTCACCCTGG ACTCCAGGGA TAGCAGGTCT

Fig. 6C

14/25

5151 TCAGATGTGG GGGGCACACT CGATTGCGCT GCTGCAGCTC TGCAATGCGG
5201 TTCCAGTCAT CCAGCTGCTC AGGCTCATCC TGGCAAGTGC CCATGTAGAA
5251 GCTGTCCTT CCTGTGGAAG GCAGGGAAGT GGAACAAAT GAGCCTGGAG
5301 TCGGCAGGTC ACCTCCTGGC CCTGGCATCT TGCCAGCCTT TGCTGCCACC
5351 TACCCATAA ACTTGAAGCC CGGCACACCA GTCTGATTCA GTGCCGAGG
5401 TGCAGGAGTA CGGCACACAG ACTATTTCTA TCCTAGGGGC TTGCTACCA
5451 CTTTCTCCCT GGAGAGGGCA GAAGAGGTCA CACGCAGAGA CTGCTACTAC
5501 ATCTTATTCA CTGCCAAGG CTTGGTGGCC AACACCCAGA GGAACAAAT
5551 AAGGACCGG AATTAATTCC CAGGGGCTCC CTGGTGCCCA AAGGACAAGA
5601 GCTTCCAAGA AGAGTCTGGC CAGCCTGGCC TTTCCAGCAG CCCATCACCG
5651 CCTGAGAAGG GCATGGAGGA CTCCCCACAG CTAAGTGTCA CAATTGTGCT
5701 GGAATCCCG GGCCCTTAAC TCTGGCTAAG AGTGCCCCCA ACACAGCCAG
5751 CCCCTAGATG GGCAGGTAAG GAAGGCCCTG AGGCTGCAGG AAGGAGGGGC
5801 AGGTGGAGCT GGATGGTAGC AAGGAGGCCA GCCTTGGATT TTTAAAAGC
5851 TTTCTCTTT TCCCTGTGCC ACGATCCACC TTCCAGTCTA ATTTGGGGT
5901 ATAGTAAGTC CCTGTAGTCC CCTCACCTGG AGGGGCCCA CTGGACACCC
5951 CGGCCTGGGA ACGACGAGCA GAACTGCGAG TGGTGGGGCG GTAGCCAGGC
6001 AAGCTGAGCA GGGCTGAGTT GCCATAATCG GGAGAACCCA GCGAGCTAG
6051 AGACTGAGTA GAGGAGGTGG CTCGCAGGCT AGCCTGGGAA GCAGGAGCAG
6101 ACCCGTGCT GTAGAACGAT GAGTTGGCGC TGTCTGGCTC TTCCACATCT
6151 AGCTTCTGGA AGACAGAGTG AATCTGTTGC AGTGTACAGT CCCTGGCACT
6201 GTACAGAAGC TTCCATTCC CTCCGAAGC CCTCAGATCC CACGGCACAT
6251 CCATGTATTC CCAACTGCTT TGCAAAGGTC CTAAAGTGT GTGTCTGCAA
6301 GAAATGGGCC TTGTCGACAG AAGCCCTCAC AAGGTGGTGC TGATGTTGTC
6351 AAGACTCTTC TACGCATTTT TTTCATGGAG TCTATTATA ATGCTTTGAG
6401 GTAGGAATG CAGAGTGTTC ATCGGCCCAT TTTGGAGATG AAGTGCAAAG

Fig. 6D

6451 AAATAAAGTG ACTAGCCCCA AATCACACTG CTAGGAAGTA TCAGAGCTGG
6501 GGCTAGGCC CATGTCTCCT GACTAGTCAG GCTCATCCCA CAGCCTCTGC
6551 TGTCCCTCAG TCCAACTTC CAGGGCCCTT ACCATGTTCC AGAACTTCCC
6601 CCAACTTCTT GGTAGCAGGG GGCACCCTAA ACACACAGGT CCCCCTGTCT
6651 GTACCAGGGG CCCCCTCTCC CCTCCTCCA AACCTCCCCT TCAAGATGTG
6701 GAAACAAAGG CAAGGCCTG CAGCCTGTCA GGCAGTCCAC TGGGCAGCAA
6751 CAATGCCTCT CAGCTGCATG GGCATGCTG GGAGGCACAG GATGGGCTGC
6801 AGCTTCGCCA CGTTCTCTCC CTTACCCTG CACAGGCTCA GTGCTACGCA
6851 TGGAGAGAAT GCTAGCCTTA GTCAGGAGGC AGGGATCTAA TCCTAGCCCT
6901 GCCTTTTCT TCAGAAGTGC CCTTAACCA GTCAGTCCC TTTTAAGAC
6951 CTCTCAGCTT TCCCACTGTA ACATGGACTG GCTGCTCATC CCTCCCTGCT
7001 CCTGACTGAG TGCCAGTGC AAAGATGCC TTAGAGAGAA GTGGGAATTG
7051 CTGACCTGTC GAC

(SEQ ID NO:5)

IL-18BPc; Protein

Length: 197 June 5, 1998 13:41 Type: P Check: 3353 ..

1 MRHNWTPDLS PLWVLLCAH VVTLVLRATP VSQTTTAATA SVRSTKDPCP
51 SQPPVFPAAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWL
101 NGSFIEHLP RLWEGSTSRE RGSTGTQLCK ALVLEQLTPA LHSTNFSCVL
151 VDPEQVVQRH VVLAQLWVRS PRRGLQEQQE LCFHMWGGKG GLCQSSL

(SEQ ID NO:6)

Fig. 6E

16/25

IL-18BPd; DNA

Length: 1360 June 19, 1998 14:55 Type: N Check: 8757 ..

1 GCGGCCGCGT CGACCACGCA GCTAAACACA GCTAACTTGA GTCTTGGAGC
51 TCCTAAAGGG AAGCTTCTGG AAAGGAAGGC TCTTCAGGAC CTCTTAGGAG
101 CCAAAGAAGA GGACGTTGTC ACAGATAAAG AGCCAGGCTC ACCAGCTCCT
151 GACGCATGCA TCATGACCAT GAGACACAAC TGGACACCAG ACCTCAGCCC
201 TTTGTGGGTC CTGCTCCTGT GTGCCACGT CGTCACTCTC CTGGTCAGAG
251 CCACACCTGT CTCGACAGACC ACCACAGCTG CCACTGCCTC AGTTAGAAGC
301 ACAAAGGACC CCTGCCCTC CCAGCCCCCA GTGTTCCAG CAGCTAAGCA
351 GTGTCCAGCA TTGGAAGTGA CCTGGCCAGA GGTGGAAGTG CCACTGAATG
401 GAACGCTGAG CTTATCCTGT GTGGCCTGCA GCCGCTTCCC CAACTTCAGC
451 ATCCTCTACT GGCTGGGCAA TGGTTCCTTC ATTGAGCACC TCCCAGGCCG
501 ACTGTGGGAG GGGAGACCA GCCGGGAACG TGGGAGCACA GGCTGGGCTG
551 AGGGCAACCT TGCCCCCAC CCAAGAAGCC CTGCCCTCCA GCCACAGCAG
601 TCCACAGCAG CAGGGTTAAG ACTCAGCACA GGGCCAGCAG CAGCACAACC
651 TTGACCAGAG CTTGGGTCCT ACCTGTCTAC CTGGAGTGAA CAGTCCCTGA
701 CTGCCTGTAG GCTGCGTGGA TGCGCAACAC ACCCCCTCCT TCTCTGCTTT
751 GGGTCCCTTC TCTACCAAAA TTCAAaCTCC ATTCCACCT ACCTAGAAAA
801 TCACAGCCTC CTTATaATGC CTCCTCCTCC TGCCATTCTC TCTCCACCTA
851 TCCATTAGCC TTCCTAACGT CCTACTCCTC AACTGCTCT ACTGCTCAGA
901 AACCACCAAG ACTGTTGATG CCTTAGCCTT GCACTCCAGG GCCCTACCTG
951 CATTTCCAC ATGACTTTCT GGAAGCCTCC CAACTATTCT TGCTTTTCCC
1001 AGACAGCTCC CACTCCCATG TCTCTGCTCA TTTAGTCCCG TCTTCTCAC
1051 CGCCCCAGCA GGGGAACGCT CAAGCCTGGT TGAATGCTG CCTCTTCAGT
1101 GAAGTCATCC TCTTTCAGCT CTGGCCGCAT TCTGCAGACT TCCTATCTTC
1151 GTGCTGTATG TTTTTTTTTT CCCCTTCAC TCTAATGGAC TGTTCCAGGG

Fig. 7

1201 AAGGGATGGG GGCAGCAGCT GCTTCGGATC CACTGTAT CTGTGTCATC
1251 CCCACATGGG TCCTCATAAA GGATTATTCA ATGGAGGCAT CCTGACATCT
1301 GTCCATTTAG GCTTCAGTTC CACTCCCAGG AACTTTGCCT GTCCCACGAG
1351 GGAGTATGGG

(SEQ ID NO:7)

IL-18BPd; protein

Length: 161 June 5, 1998 13:40 Type: P Check: 2239 ..

1 MRHNWTPDLS PLWVLLCAH VVTLVRATP VSQTTAATA SVRSTKDPCP
51 SQPPVFPAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWLG
101 NGSFIEHLP RLWEGSTSRE RGSTGWAEGN LAPHRSPAL QPQSTAAGL
151 RLSTGPAAAQ P

(SEQ ID NO:8)

Fig. 7A

18/25

HuiL-18BP gene

Length: 7812 July 15, 1998 11:55 Type: N Check: 7058 ..

1 GTCGACGGTA CCCCCGGGAA AGATTTAATA CGACTCACTA TAGGGCGGGA
51 CAGAATTGAT CTGTGAGAGA CTCATCTAGT TCATACCCTA GGTGACCCTG
101 GGGGTGGCAT GGGGGTAGAT TAGAGATCCC AGTCTGGTAT CCTCTGGAGA
151 GTAGGAGTCC CAGGAGCTGA AGGTTTCTGG CCACTGAACT TTGGCTAAAG
201 CAGAGGTGTC ACAGCTGCTC AAGATTCCTT GGTAAAAAAG TGAAAGTGAA
251 ATAGAGGGTC GGGGCAGTGC TTTCCAGAA GGATTGCTCG GCATCCTGCC
301 CTTCCAGAA GCAGCTCTGG TGCTGAAGAG AGCACTGCCT CCCTGTGTGA
351 CTGGGTGAGT CCATATTCTC TCTTTGGGTC TCAATTTTGC CTCCCTAAT
401 GAAGGGGTAA GATTGGACTA GGTAAGCATC TTACAACCAT TTGTGGTCAT
451 GAGAGCTGGG GTGGGGAAGG ATTGTCACTT GACCCCCCA GCTCTGTTTC
501 TAAGTGCTGA AAGAGCTCCA GGCTATGCTA CGGGAGGAGA AGCCAGCTAC
551 TGAGAAAAG CCAGCTACTG AGAAAAGCG GGAGTGGTTT ACCATTCTCC
601 TCCCCACCT TTCACCAGAG AAGAGGACGT TGTCACACAT AAAGAGCCAG
651 GCTCACCAGC TCCTGACGCA TGCATCATGA CCATGAGACA CAACTGGACA
701 CCAGGTAGGC CTTGGGCTA CGCATGGGCA GCGGGGTAG GGTGAGGTCT
751 ATGAACAGAA TGGAGCAATG GGCTAACCCG GAGCCTTCAC TCCAAGGCAA
801 ACCACCCAGC GCACCTGGTG CTGTTGCTTT AAGAACCTGG GCAGATATTG
851 TAGCTCTGGC TCCAGTCTAA AGCTTCTCTG TACTCTGTTC AATAAAGGGC
901 TAAGGGGTGG GTGCTGAGGG GTCCCTCTTC CCGCTCTGAT TCCCTGGCTA
951 GAACCCAGAC ATCTCTGGGC TGGAGTTACA TCCTTACCCG GGCAGCCCA
1001 TCTGTCTCA GAGCCGCTGA CCTGTAAC TGCTTTCTC AGACCTCAGC
1051 CCTTTGTGGG TCCTGCTCCT GTGTGCCAC GTCGTCACTC TCCTGGTCAG
1101 AGCCACACCT GTCTCGCAGA CCACCACAGC TGCCACTGCC TCAGTTAGAA
1151 GCACAAAGGA CCCCTGCCCC TCCAGCCCC CAGTGTTCAG AGCAGCTAAG

Fig. 8

SUBSTITUTE SHEET (RULE 26)

1201 CAGTGTCCAG CATTGGAAGT GACCTGGCCA GAGGTGGAAG TGCCACTGAG
1251 TAAGAAGCAC AGTGGTGGAG GGTGGGCTAT GGGCACAGAG GTTCCCAGGG
1301 TCGGGTTGAC TCCTGAGCGC CAGTCCCCTT CTGCCCATGT ACCACCAGCT
1351 GAGCCAGCTG GGCTGAGCAC GCACCATTCT CCCTCCCCAA CCCAGTGTC
1401 TGGGTGCAGG CTGGCGCAG CTCCTAAGAT GCTCCCTATC AAATAGGACA
1451 GAGAACTCAA GACATAAGTA ATGGTCACAG GACCTCCCAG AGCCTTGTT
1501 GCAGTGGACC CCAAGGCCAG CCCCTCCACC CAGAGCCTGC TGGCCTCTGG
1551 CCATCTCAGA GGAGCAGCAG CCATCCAGCA CTGCCTCTGT CACCTGGGCT
1601 CCCAAGTCAC CGAGGCTGGG CACTAGAAAA GGTTCATCTG AGGAGACAGG
1651 TTCAGAAGAG GATTCATCAC GTGAACCAAG GACCATTCTC CACATTCCCC
1701 GTGTTTAGGG CTAGGGCCTC TCGGAGACAA CTGCCTTCT GTAACGGAGC
1751 TTCCCACCTA GGTGGTGTGC AGAGCAGTTC TCTAGTTCC AGATGCATGG
1801 GGAAGTGGGG GAGCTGGCAG AGAGGGCACA GCAGAGCAGG GTAGGGGAAG
1851 GGCCTGCTCT TCTGAAGAGC TAACTGCTGC CTGTGTCCCT AGATGGAACG
1901 CTGAGCTTAT CCTGTGTGGC CTGCAGCCGC TTCCCCAACT TCAGCATCTC
1951 CTAAGGCTG GGCAATGGTT CCTTCATTGA GCACCTCCA GCGCGACTGT
2001 GGGAGGGGAG CACCAGGTGA GGGTCGCAGC AGCCAGGTGG GTGGGAAGGA
2051 AGCCTTCTGC GGCCTTCTCA TGACCTTTC TTCCCTTCG CTCAGCCGG
2101 GAACGTGGGA GCACAGGTAC GCAGCTGTGC AAGGCCTTGG TGCTGGAGCA
2151 GCTGACCCCT GCCCTGCACA GCACCAACTT CTCCTGTGTG CTCGTGGACC
2201 CTGAACAGGT TGTCCAGCGT CACGTCGTCC TGGCCCAGCT CTGGGTGAGG
2251 AGCCCAAGGA GAGGCCTCCA GGAACAGGAG GAGCTCTGCT TCCATATGTG
2301 GGGAGGAAAG GGTGGGCTCT GCCAGAGCAG CCTGTGAACT AATGCCCAGC
2351 ATTCCTCAAG GTCAGCCAGA CAAAAAGGAA CTTAGGTCTT GGGCAGAGGA
2401 GGTGTAGCCT GGGGCAAAGT GATGAGATGT CCCTCCTTC CTTGGCCTGA
2451 TCCTTGCTCG CCTCACTTC CCTAGGCTGG GCTGAGGGCA ACCTTGCCCC

Fig. 8A

SUBSTITUTE SHEET (RULE 26)

2501 CCACCCAAGA AGCCCTGCCC TCCAGCCACA GCAGTCCACA GCAGCAGGGT
2551 TAAGACTCAG CACAGGGCCA GCAGCAGCAC AACCTTGACC AGAGCTTGGG
2601 TCCTACCTGT CTACCTGGAG TGAACAGTCC CTGACTGCCT GTAGGCTGCG
2651 TGGATGCGCA ACACACCCCC TCCTTCTCTG CTTTGGGTCC CTTCTCTCAC
2701 CAAATTCAAA CTCCATTCCC ACCTACCTAG AAAATCACAG CCTCCTTATA
2751 ATGCCTCCTC CTCCTGCCAT TCTCTCTCCA CCTATCCATT AGCCTTCCTA
2801 ACGTCTACT CCTCACACTG CTCTACTGCT CAGAAACCAC CAAGACTGTT
2851 GATGCCTTAG CTTGCACTC CAGGGCCCTA CCTGCATTTT CCACATGACT
2901 TTCTGGAAGC CTCCCAACTA TTCTTGCTTT TCCCAGACAG CTCCCCTCC
2951 CATGTCTCTG CTCATTTAGT CCCGTCTTCC TCACCGCCCC AGCAGGGGAA
3001 CGCTCAAGCC TGGTTGAAAT GCTGCCTCTT CAGTGAAGTC ATCCTCTTTC
3051 AGCTCTGGCC GCATTCTGCA GACTTCCTAT CTTCGTGCTG TATGTTTTTT
3101 TTTTCCCCT TCACTTAAT GGACTGTTC AGGGAAGGGA TGGGGGCAGC
3151 AGCTGCTTCG GATCCACACT GTATCTGTGT CATCCCCACA TGGGTCCTCA
3201 TAAAGGATTA TTCAATGGAG GCATCCTGAC ATCTGTTCAT TTAGGCTTCA
3251 GTTCCACTCC CAGGAACTTT GCCTGTCCCA CGAGGGAGTA TGGGAGAGAT
3301 GGACTGCCAC ACAGAAGCTG AAGACAACAC CTGCTTCAGG GGAACACAGG
3351 CGCTTGAAAA AGAAAAGAGA GAACAGCCCA TAATGCTCCC CGGGAGCAGA
3401 GGCCACTAAT GGAGAGTGGG AAGAGCCTGG AAAGATGTGG CCTCAGGAAA
3451 AGGGATGAGA GAAAGGAGGT GGTATGGAAG ACTCAGCAGG AACAAGGTAG
3501 GCTTCAAAGA GCCTATATTC CTCTTTTCC CACACCGATC AAGTCAACTC
3551 AGTACTCACG GGAGAAAAAT AGACTTTATT TACAAGTAAT AACATTTAGA
3601 AAAGATCCAT CCCC GGCCCT TAAAAACCTT CCCATCACTC CAAATCCCAC
3651 CCCAGTGCAA GTCTGGGGAA GGTAGGTGT GAGCTGCTGC TGAAGGCTGT
3701 CCCCCAACCC CACTCCTGAG ACACAGGGCC CATCCGTCCT GGGAAAGAGC
3751 ATCCTCTGGC AGGTGCTCCC ACCAGGTCAG ACCCAGTCCT GGACTTCAAG

Fig. 8B

3801 AGTGAGGGCC CCTGCTGGGC CCAGCCACCA GGACAGCAGG AACCAGGGCC
3851 TACTCCTCTT ATGGTCCCTT CTAGATCCAG AGGCTAAGAG GAAGACTGGC
3901 CAGGCCCAAG GACCCAGCCA TCAAAACCAG CCTCAAATCT GGTGTGATG
3951 GAGAAGTGAC TTTGCTTTAA GAAAAAGGA GGCAAGGTAG GGAGAGCGCC
4001 CACTGTGCC ATGCTCCAGG CCCCTGGGC CAGCTCCGAG AAGGCCACG
4051 TGAAGGACCA GGGACCAGGC CAGGGTGGG GCAGGCATCA CTGTCTCTAG
4101 GGGTTTGGCT ACTGTTGGCC TGGGAGCTGA GAGAAGGCAC TGAGAGGGAC
4151 AGTAGGCGGA GGACCAGGTG ACGGCAGCAT CGGGGACACA GGTGGGGCCA
4201 CTCACTGGTA CTGGCCCTTT AGTGCTTTGC CTGAAAGAGA CACAGTCACA
4251 TGGCCAGATG AGAACTTGGC AACTAGCCT GCACCCACTG GCTGGGAAGA
4301 TCTCTTCTG CTCCCAGCC CCTGTCTGGA TCCCTCCCT TGTGAGCCCC
4351 AGGGTTATCA GTTGCTGGCT GTGCCAGAGC AGCTCTGGGT GCTCTCCATG
4401 AGAATGGGGC CATCTGTCTT CTCTCCTTGG AGAGGAGCTA CCAGGACAGG
4451 GACACCTCTT ACCCCACACC CTCCAGCAGC CTGGCGTGGC CCCATCTTGG
4501 ATGCTACTTG GTGGGGCGGT CTGGGGGGTG CCCATGTCTT CATCGGGTTT
4551 CCCTCCCCCA TCCTGCCAGT GCCTCTACCT TGCCCTTGGC TCGAGGGGTG
4601 GCACCAATGG CGGCAGCAGT GGCGGCGCTG GCTGTGGTGG TGGCAATGCC
4651 CGGAGAACGG CGGGTTCCAC TGCGAGTGTT GGGGAAGCC TTGGACAGGG
4701 CCTTCTTTGA GGCTCCCCGC CGCAGAAGGC TGTTCCCTAG CTTCTTGGGT
4751 GTGTTGAGGA TGCTGAAGGC CATCGACTGG CGCCGGTCAAG CCTGCAAGGA
4801 AGGGCTGTCA GACCGGGAGA CCCAATGCTG CCTTCCCAGG CCAGCGTGCT
4851 GTGCCAGCT GTACCAGCAA GGTCCCGCCA GGGCGTCGCT TCATCCCCCT
4901 TCAGCCCCAG CCTCACCTGT TTAGTAGAAG CTGGAGCTGC TTTCTTCTGG
4951 GCCTCAGTAG TGCTCTGTTT GCGCCCTTCA TGTCGGTCTC GGGGAGTCAT
5001 GGGGCGTGGG AAACAGCTGG TGGCCTTCTT AGACTATGGA GAAGAGGACA
5051 GTTAGGCAGA CAGTAGCAAG AGGAGTCACA TCTGAAGCCA GGTGTCTTGT

Fig. 8C

5101 CCTCTCAGAG CTGAGTGGAC CTTGTAAGTC AACGTGCAAC CTGCTCCCTT
5151 TCCCAACTCT GGGCCAGATC CTTCCCTTCC CAACAGTTCC CATCCATGGG
5201 TCAGGCCCTT GGAGAGAGGG AAAGAGAGGG GGAAGTGAGG GAAGGAGAGA
5251 GAAGGCTCCC TTTAGTCCTT GGTGAGCTGG GCCTGACCTG AGCACAGTGC
5301 TGGAGTAACA CCCAGGAGCC ACCGCGCCTA CCTCAGGAGT TCCAGGGCCC
5351 TGGTGGGGCT CTAGGGAGAC CCGTTTGC GC TGCTGCCGGG TGGTGATGCC
5401 AGTGCCCTCG GCTATCTGGA TTGGCTGCAT GCTGGCTCGG CGCAGGGTCT
5451 CTTGGGGGTC TCCAGTTTTC ATCTCCTCAT CTGTGATGGT GCCCAGGCTC
5501 AGGGAAGGCT GCATGGGTGG AAGAGGTGGT CAGTGGACCA TAGCTGTATG
5551 GAGATGGAGG AGGACCTGGG GCTGTTCCAG AACTCTACAC TCGCCCGACA
5601 CTTATGGTCG GGACCCTTCC TGCCTACGAG GTAGAAAGAC ACAAGCCTCC
5651 TTTCTGTTC TGCTTTCTAC CTAAGCCCTG GGCAAATGGC ACAAGCAGTG
5701 CAGTCCTGAC CAGATTCCTC TCTGAGCTCC TGCCTACCCC CAGGGACTTC
5751 ACCCCTGAGT GCCCTCCAGC TGTCTGTTCC ACCTGGAACA TGAGAAGGTC
5801 ACCCCTTCCC CTCTTCGGCC AGTCAGTGAT CCAGGGCCCT AGTGCTCAGG
5851 CTAGATCAGC AGGTGGGATT CCAAGGAAGG GCAGGGATGG GAGGCCCTGC
5901 ACAGTGACCC CAGGCCTCAC CCTGGACTCC AGGGATAGCA GGTCTTCAGA
5951 TGTGGGGGGC AACTCGATT GCGCTGCTGC AGCTCTGCAA TGCGGTTC CA
6001 GTCATCCAGC TGCTCAGGCT CATCCTGGCA AGTGCCCATG TAGAAGCTGT
6051 TCCTTCCTGT GGAAGGCAGG GAAGTGGGAA CAAATGAGCC TGGAGTCGGC
6101 AGGTCACCTC CTGGCCCTGG CATCTTGCCA GCCTTTGCTG CCACCTACCC
6151 CATAAACTTG AAGCCCGGCA CACCAGTCTG ATTCAGTGCC GCAGGTGCAG
6201 GAGTACGGCA CACAGACTAT TTCTATCCTA GGGGCTTGCT CACCACCTTC
6251 TCCCTGGAGA GGGCAGAAGA GGTACACGC AGAGACTGCT ACTACATCTT
6301 ATTCACCTGC CAAGGCTTGG TGGCCAACAC CCAGAGGAAC AAATTAAGGA
6351 CCGGGAATTA ATTCCCAGGG GCTCCCTGGT GCCCAAAGGA CAAGAGCTTC

Fig. 8D

6401 CAAGAAGAGT CTGGCCAGCC TGGCCTTCC AGCAGCCAT CACCGCCTGA
6451 GAAGGGCATG GAGGACTCCC CACAGCTAAG TGTCACAATT GTGCTGGGAA
6501 TCCCGGGCCC TTAACCTGCG CTAAGAGTGC CCCCAACACA GCCAGCCCT
6551 AGATGGGCAG GTAAGGAAGG CCCTGAGGCT GCAGGAAGGA GGGGCAGGTG
6601 GAGCTGGATG GTAGCAAGGA GGCCAGCCTT GGATTTTTAA AAAGCTTTCC
6651 TCTTTCCCT GTGCCACGAT CCACCTTCCA GTCTAATTTT GGGGTATAGT
6701 AAGTCCCTGT AGTCCCTCA CCTGGAGGGG CCCCACTGGA CACCCCGGCC
6751 TGGGAACGAC GAGCAGAACT GCGAGTGGTG GGGCGGTAGC CAGGCAAGCT
6801 GAGCAGGGCT GAGTTGCCAT AATCGGGAGA ACCCAGGCGA GCTAGAGACT
6851 GAGTAGAGGA GGTGGCTCGC AGGCTAGCCT GGAAGCAGG AGCAGACCGC
6901 GTGCTGTAGA ACGATGAGTT GGCCTGTCT GGCTCTTCCA CATCTAGCTT
6951 CTGGAAGACA GAGTGAATCT GTTGCAGTGT ACAGTCCCTG GCACTGTACA
7001 GAAGTTCCTC ATCCCTTCC GAAGCCCTCA GATCCACGG CACATCCATG
7051 TATTCCCAAC TGCTTTGCAA AGGTCCTTAA AGTGTGTGTC TGCAAGAAAT
7101 GGGCCTTGTG GACAGAAGCC CTCACAAGGT GGTGCTGATG TTGCAAGAC
7151 TCTTCTACGC ATTTTTTTCA TGGAGTCTAT TCATAATGCT TTGAGGTAGG
7201 GAATGCAGAG TGTTTATCGG CCCATTTTGG AGATGAAGTG CAAAGAAATA
7251 AAGTGACTAG CCCCAAATCA CACTGCTAGG AAGTATCAGA GCTGGGGCTA
7301 GGCCCATGT CTCCTGACTA GTCAGGCTCA TCCCACAGCC TCTGCTGTCC
7351 CTCAGTCCAA ACTTCCAGGG CCCTTACCAT GTTCCAGAAC TTCCCCAAC
7401 TTCTTGGTAG CAGGGGGCAC CCTAAACACA CAGGTCCCCC CTGCTGTACC
7451 AGGGGCCCCC TCTCCCTCC TCCAAACCT CCCCTTCAAG ATGTGAAAC
7501 AAAGGCAAGG GCCTGCAGCC TGTCAGGCAG TCCACTGGGC AGCAACAATG
7551 CCTCTCAGCT GCATGGGGCA TGCTGGGAGG CACAGGATGG GCTGCAGCTT
7601 CGCCACGTTT TCTCCCTTCA CCCTGCACAG GCTCAGTGCT ACGCATGGAG
7651 AGAATGCTAG CCTTAGTCAG GAGGCAGGGA TCTAATCCTA GCCCTGCCTT

Fig. 8E

WO 99/09063

PCT/IL98/00379

24/25

7701 TTTCTTCAGA AGTGCCCTTA ACCAAGTCAC TGCCCTTTT AAGACCTCTC

7751 AGCTTTCCCA CTGTAACATG GACTGGCTGC TCATCCCTCC CTGCTCCTGA

7801 CTGAGTGCCC AG

(SEQ ID NO:9)

Fig. 8F




Fig. 9 A-D